Premier Graphene (BIEI) S-1/A 2 Jul 18 IPO registration (amended) Financial data

Document and Entity Information

Document and Entity Information	3 Months Ended
	Mar. 31, 2018
Document And Entity Information
Entity Registrant Name	PREMIER BIOMEDICAL INC
Entity Central Index Key	1,515,740
Document Type	S-1/A
Document Period End Date	Mar. 31, 2018
Amendment Flag	true
Amendment Description	Amendment
Current Fiscal Year End Date	--12-31
Is Entity a Well-known Seasoned Issuer	No
Is Entity a Voluntary Filer	No
Is Entity's Reporting Status Current	Yes
Entity Filer Category	Smaller Reporting Company
Document Fiscal Year Focus	2,018

BALANCE SHEETS

BALANCE SHEETS - USD ($)	Mar. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Current assets:
Cash	$ 79,221	$ 83,704	$ 22,437
Accounts receivable		312
Inventory	79,410	84,763
Other current assets	33,327	34,824	11,430
Total current assets	191,958	203,603	33,867
Property and equipment, net	6,916	5,478	5,100
Total assets	198,874	209,081	38,967
Current liabilities:
Accounts payable	346,856	346,814	220,740
Accounts payable, related parties	40,904	41,382	52,489
Accrued interest	9,125	5,840	18,026
Accrued interest, related parties			3,570
Convertible notes payable, net of discounts of $30,010 and $149,456 at December 31, 2017 and 2016, respectively, currently in default	154,778	169,990	153,024
Notes payable, related parties			30,000
Derivative liabilities	1,574,343	2,255,781	221,822
Total current liabilities	2,126,006	2,819,807	699,671
Total liabilities	2,126,006	2,819,807	699,671
Commitments and contingencies
Stockholders' equity (deficit):
Preferred stock, $0.001 par value, 10,000,000 shares authorized, 2,000,000 and -0- shares issued and outstanding at December 31, 2017 and 2016, respectively	2,000	2,000	2,000
Common stock, $0.00001 par value, 1,000,000,000 shares authorized, 637,840,677 and 304,556,650 shares issued and outstanding at December 31, 2017 and 2016, respectively	7,473	6,378	3,046
Additional paid in capital	13,825,883	13,435,903	11,899,504
Subscriptions payable, consisting of 63,675,678 and -0- shares at December 31, 2017 and 2016, respectively		273,805
Accumulated deficit	(15,762,488)	(16,328,812)	(12,565,254)
Total stockholders' equity (deficit)	(1,927,132)	(2,610,726)	(660,704)
Total liabilities and stockholders' equity (deficit)	$ 198,874	$ 209,081	$ 38,967

BALANCE SHEETS (Parenthetical)

BALANCE SHEETS (Parenthetical) - USD ($)	Mar. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Current liabilities:
Convertible notes payable, net of discounts	$ 40,222	$ 30,010	$ 149,456
Stockholders' equity (deficit):
Preferred stock, par value	$ 0.001	$ 0.001	$ 0.001
Preferred stock, authorized shares	10,000,000	10,000,000	10,000,000
Preferred stock, issued shares	2,000,000	2,000,000	0
Preferred stock, outstanding shares	2,000,000	2,000,000	0
Common stock, par value	$ 0.00001	$ 0.00001	$ 0.00001
Common stock, authorized shares	1,000,000,000	1,000,000,000	1,000,000,000
Common stock, issued shares	747,306,550	637,840,677	304,556,650
Common stock, outstanding shares	747,306,550	637,840,677	304,556,650
Subscriptions payable, shares	0	63,675,678	0

STATEMENTS OF OPERATIONS

STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017	Dec. 31, 2016
Statements Of Operations
Revenue	$ 10,395		$ 39,761
Cost of goods sold	6,058		25,439
Gross Profit	4,337		14,322
Operating expenses:
Research and development			184,315	113,862
General and administrative	34,492	33,059	196,670	191,379
Professional fees	39,616	41,147	923,175	332,650
Total operating expenses	74,108	74,206	1,304,160	637,891
Net operating loss	(69,771)	(74,206)	(1,289,838)	(637,891)
Other income (expense):
Interest expense	(64,145)	(152,747)	(351,502)	(817,423)
Other expense				(340,647)
Gain on settlement				53,788
Change in derivative liabilities	700,240	(5,100,091)	(2,115,986)	(26,048)
Equity in losses of investment in joint venture		(2,058)	(6,232)
Total other income (expense)	636,095	(5,254,896)	(2,473,720)	(1,130,330)
Net income (loss)	$ 566,324	$ (5,329,102)	$ (3,763,558)	$ (1,768,221)
Weighted average number of common shares outstanding - basic and fully diluted			489,686,283	151,651,420
Net loss per share - basic and fully diluted			$ (0.01)	$ (0.01)
Weighted average number of common shares outstanding - basic	718,803,900	401,283,532
Weighted average number of common shares outstanding - fully diluted	721,796,400	402,283,532
Net loss per share - basic	$ 0	$ (0.01)
Net loss per share - fully diluted	$ 0	$ (0.01)

STATEMENT OF STOCKHOLDERS' EQUI

STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)	Preferred Stock	Common Stock	Additional Paid-In Capital	Subscriptions Payable	Accumulated Deficit	Total
Beginning Balance, Shares at Dec. 31, 2015		82,331,062
Beginning Balance, Amount at Dec. 31, 2015		$ 823	$ 10,370,651		$ (10,797,033)	$ (425,559)
Common stock issued on equity line of credit, Shares		27,952,890
Common stock issued on equity line of credit, Amount		$ 280	143,240			143,520
Common stock issued on debt conversions, Shares		165,196,985
Common stock issued on debt conversions, Amount		$ 1,652	736,064			737,716
Exercise of preferred stock warrants at $0.001 per share, related parties, Shares	2,000,000
Exercise of preferred stock warrants at $0.001 per share, related parties, Amount	$ 2,000					2,000
Exercise of warrants at $0.00001 per share, related party, Shares		20,000,000
Exercise of warrants at $0.00001 per share, related party, Amount		$ 200				200
Exercise of cashless warrants at $0.00001 per share, Shares		2,248,846
Exercise of cashless warrants at $0.00001 per share, Amount		$ 22	(22)
Shares issued for serttlement of reimbursements, related party, Shares		600,000
Shares issued for serttlement of reimbursements, related party, Amount		$ 6	13,759			$ 13,765
Shares issued for services, Shares		6,226,867
Shares issued for services, Amount		$ 63	70,558			$ 70,621
Amortization of warrants granted for services, related parties			25,030			25,030
Amortization of warrants granted for services			14,739			14,739
Adjustments to derivative liability due to debt conversions			525,485			525,485
Net loss					(1,768,221)	(1,768,221)
Ending Balance, Shares at Dec. 31, 2016	2,000,000	304,556,650
Ending Balance, Amount at Dec. 31, 2016	$ 2,000	$ 3,046	11,899,504		(12,565,254)	(660,704)
Common stock issued on equity line of credit, Shares		5,147,110
Common stock issued on equity line of credit, Amount		$ 51	18,272			18,323
Common stock issued on debt conversions, Shares		199,342,008
Common stock issued on debt conversions, Amount		$ 1,993	421,204			423,197
Exercise of warrants at $0.00001 per share, related party, Shares		7,000,000
Exercise of warrants at $0.00001 per share, related party, Amount		$ 70				70
Shares issued for services, Shares		9,000,000
Shares issued for services, Amount		$ 90	84,510			84,600
Adjustments to derivative liability due to debt conversions			303,542			303,542
Common stock sold for cash, Shares		40,000,002
Common stock sold for cash, Amount		$ 400	284,600			285,000
Shares issued for services on terminated offering, Shares		72,794,907
Shares issued for services on terminated offering, Amount		$ 728	312,290	273,805		586,823
Warrants issued for services, related parties			102,364			102,364
Warrants issued for services			9,617			9,617
Net loss					(3,763,558)	(3,763,558)
Ending Balance, Shares at Dec. 31, 2017	2,000,000	637,840,677
Ending Balance, Amount at Dec. 31, 2017	$ 2,000	$ 6,378	$ 13,435,903	$ 273,805	$ (16,328,812)	(2,610,726)
Net loss						566,324
Ending Balance, Amount at Mar. 31, 2018						$ (1,927,132)

STATEMENTS OF CASH FLOWS

STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017	Dec. 31, 2016
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ 566,324	$ (5,329,102)	$ (3,763,558)	$ (1,768,221)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	591	528	2,316	2,083
Equity in losses of joint venture investment		2,058	6,232
Change in fair market value of derivative liabilities	(700,240)	5,100,091	2,115,986	26,048
Amortization of debt discounts	60,860	149,456	340,961	749,162
Gain on settlement of judgment				(53,788)
Stock based compensation, related parties			102,364	25,030
Stock based compensation			681,040	85,360
Decrease (increase) in assets:
Accounts receivable	312		(312)
Inventory	5,353		(84,763)
Other current assets	1,497	1,922	(23,394)	(2,264)
Increase (decrease) in liabilities:
Accounts payable	42	(42,297)	126,074	32,475
Accounts payable, related parties	(478)	236	(11,107)	11,586
Accrued interest	3,285	2,691	8,531	65,860
Accrued interest, related parties		600	(3,570)	2,400
Judgment payable				340,647
Net cash used in operating activities	(62,454)	(113,817)	(509,432)	(483,622)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property and equipment	(2,029)		(2,694)	(3,536)
Investment in joint venture		(2,058)
Net cash used in investing activities	(2,029)	(2,058)	(2,694)	(3,536)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from sale of stock, net of offering costs		285,000	285,000
Proceeds from sale of stock on equity line of credit		18,323	18,323	143,520
Proceeds from exercise of warrants, related party			70	2,200
Proceeds from convertible notes payable	60,000		300,000	417,500
Repayments of convertible notes payable				(89,039)
Repayments of notes payable, related parties			(30,000)
Net cash provided by financing activities	60,000	303,323	573,393	474,181
NET CHANGE IN CASH	(4,483)	187,448	61,267	(12,977)
CASH AT BEGINNING OF PERIOD	83,704	22,437	22,437	35,414
CASH AT END OF PERIOD	79,221	209,885	83,704	22,437
SUPPLEMENTAL INFORMATION:
Interest paid			5,580	13,539
Income taxes paid
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Value of debt discounts	60,000		221,515	571,183
Value of derivative adjustment due to debt conversions	52,270	229,043	303,542	525,485
Value of shares issued for conversion of debt	$ 65,000	$ 323,197	423,197	737,716
Convertible note issued in settlement of judgment payable				300,000
Common stock issued for settlement of accounts payable, related party				13,765
Cashless exercise of common stock warrants, 2,250,000 warrants exercised				$ 22

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Notes to Financial Statements
Note 1 - Basis of Presentation and Significant Accounting Policies	Basis of Presentation The accompanying unaudited, condensed financial statements of Premier Biomedical, Inc. (“the Company”) have been prepared pursuant to rules and regulations of the Securities and Exchange Commission (“SEC”) and, therefore, do not include all information and footnote disclosures normally included in audited financial statements. However, these statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary for fair presentation of the information contained therein. It is suggested that these statements be read in conjunction with the financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Cash and Cash Equivalents We maintain cash balances in non-interest-bearing accounts, which do not currently exceed federally insured limits. For the purpose of the statements of cash flows, all highly liquid investments with an original maturity of three months or less are considered to be cash equivalents. Patent Rights and Applications Patent rights and applications costs include the acquisition costs and costs incurred for the filing of patents. Patent rights and applications are amortized on a straight-line basis over the legal life of the patent rights beginning at the time the patents are approved. Patent costs for unsuccessful patent applications are expensed when the application is terminated. Fair Value of Financial Instruments Under FASB ASC 820-10-05, the Financial Accounting Standards Board establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosures about fair value measurements. This Statement reaffirms that fair value is the relevant measurement attribute. The adoption of this standard did not have a material effect on the Company’s financial statements as reflected herein. The carrying amounts of cash, prepaid expenses and accrued expenses reported on the balance sheet are estimated by management to approximate fair value primarily due to the short term nature of the instruments. Basic and Diluted Loss Per Share Basic earnings per share (“EPS”) are computed by dividing net income (the numerator) by the weighted average number of common shares outstanding for the period (the denominator). Diluted EPS is computed by dividing net income by the weighted average number of common shares and potential common shares outstanding (if dilutive) during each period. Potential common shares include stock options, warrants and restricted stock. The number of potential common shares outstanding relating to stock options, warrants and restricted stock is computed using the treasury stock method. The reconciliation of the denominators used to calculate basic EPS and diluted EPS for the three months ended March 31, 2018 and 2017 are as follows: For the Three Months Ended March 31, 2018 2017 Weighted average common shares outstanding – basic 718,803,900 401,283,532 Plus: Potentially dilutive common shares: Stock options and warrants 2,992,500 - Weighted average common shares outstanding – diluted 721,796,400 401,283,532 For the three months ended March 31, 2017, potential dilutive securities had an anti-dilutive effect and were not included in the calculation of diluted net loss per common share. Stock options and warrants excluded from the calculation of diluted EPS because their effect was anti-dilutive were 61,440,000 and 110,690,004 as of March 31, 2018 and 2017, respectively. Stock-Based Compensation Under FASB ASC 718-10-30-2, all share-based payments to employees, including grants of employee stock options, to be recognized in the income statement based on their fair values. Pro forma disclosure is no longer an alternative. The Company had no stock based compensation issuances during the three months ended March 31, 2018 and 2017. Revenue Recognition Sales on fixed price contracts are recorded when services are earned, the earnings process is complete or substantially complete, and the revenue is measurable and collectability is reasonably assured. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded. The Company defers any revenue from sales in which payment has been received, but the earnings process has not occurred. Sales commenced on July 5, 2017 with the termination of our joint venture and are recognized upon shipment of goods, which are typically paid for at the time of order. Advertising and Promotion All costs associated with advertising and promoting products are expensed as incurred. These expenses were $9,925 and $67,216 for the three months ended March 31, 2018 and 2017, respectively. Income Taxes Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided for significant deferred tax assets when it is more likely than not, that such asset will not be recovered through future operations. Uncertain Tax Positions In accordance with ASC 740, “Income Taxes” (“ASC 740”), the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be capable of withstanding examination by the taxing authorities based on the technical merits of the position. These standards prescribe a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. These standards also provide guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. Various taxing authorities periodically audit the Company’s income tax returns. These audits include questions regarding the Company’s tax filing positions, including the timing and amount of deductions and the allocation of income to various tax jurisdictions. In evaluating the exposures connected with these various tax filing positions, including state and local taxes, the Company records allowances for probable exposures. A number of years may elapse before a particular matter, for which an allowance has been established, is audited and fully resolved. The Company has not yet undergone an examination by any taxing authorities. The assessment of the Company’s tax position relies on the judgment of management to estimate the exposures associated with the Company’s various filing positions. Recent Accounting Pronouncements Effective January 1, 2018, the Company adopted ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts to perform pilot studies by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. For the comparative periods, revenue has not been adjusted and continues to be reported under ASC 605 — Revenue Recognition. Under ASC 605, revenue is recognized when the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) the performance of service has been rendered to a customer or delivery has occurred; (3) the amount of fee to be paid by a customer is fixed and determinable; and (4) the collectability of the fee is reasonably assured. There was no impact on the Company’s financial statements as a result of adopting Topic 606 for the three months ended March 31, 2018 and 2017, or the twelve months ended December 31, 2017. In May 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) 2017-09 , Compensation — Stock Compensation (Topic 718): Scope of Modification Accounting. ASU 2017-9 No other new accounting pronouncements, issued or effective during the three months ended March 31, 2018, have had or are expected to have a significant impact on the Company’s financial statements.	Nature of Business Premier Biomedical, Inc. (“the Company”) was incorporated in the State of Nevada on May 10, 2010 (“Inception”). The Company was formed to develop and market medications and procedures that address a significant number of the most highly visible health issues currently affecting mankind. Our current focus is primarily on the development and distribution of our pain products. These statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary for fair presentation of the information contained therein. Equity Method Investee companies that are not consolidated, but over which the Company exercises significant influence, are accounted for under the equity method of accounting. Whether or not the Company exercises significant influence with respect to an Investee depends on an evaluation of several factors including, among others, representation on the Investee company’s board of directors and ownership level, which is generally a 20% to 50% interest in the voting securities of the Investee company. Under the equity method of accounting, an Investee company’s accounts are not reflected within the Company’s Balance Sheets and Statements of Operations; however, the Company’s share of the earnings or losses of the Investee company is reflected in the caption “Equity in losses of unconsolidated entity” in the Statements of Operations. The Company’s carrying value in an equity method Investee company is typically reflected in the caption “Investment in Joint Venture.” in the Company’s Balance Sheets. As of December 31, 2017, our share of losses from the investee company exceeded our basis, therefore the investment is not currently presented on the balance sheet. U.S. GAAP considers a change in reporting entity to include “changing specific subsidiaries that make up the group of entities for which consolidated financial statements are presented.” Circumstances may arise where a parent’s controlling financial interest (e.g., generally an ownership interest in excess of 50 percent of the outstanding voting stock) is reduced to a noncontrolling investment that still enables it to exercise significant influence over the operating and financial policies of the investee. A change that results from changed facts and circumstances (such as a partial sale of a subsidiary), where there was only one acceptable method of accounting prior to the change in circumstances (consolidation) and only one acceptable method of accounting after the change (equity method accounting), is not a change in reporting entity and is not be accounted for retrospectively. Accordingly, a change from a controlling interest to a noncontrolling investment accounted for under the equity method is accounted for prospectively from the date of change in control. When the Company’s carrying value in an equity method Investee company is reduced to zero, no further losses are recorded in the Company’s consolidated financial statements unless the Company guaranteed obligations of the Investee company or has committed additional funding. When the Investee company subsequently reports income, the Company will not record its share of such income until it equals the amount of its share of losses not previously recognized. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Cash and Cash Equivalents We maintain cash balances in non-interest-bearing accounts, which do not currently exceed federally insured limits. For the purpose of the statements of cash flows, all highly liquid investments with an original maturity of three months or less are considered to be cash equivalents. Patent Rights and Applications Patent rights and applications costs include the acquisition costs and costs incurred for the filing of patents. Patent rights and applications are amortized on a straight-line basis over the legal life of the patent rights beginning at the time the patents are approved. Patent costs for unsuccessful patent applications are expensed when the application is terminated. Fair Value of Financial Instruments Under FASB ASC 820-10-05, the Financial Accounting Standards Board establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosures about fair value measurements. This Statement reaffirms that fair value is the relevant measurement attribute. The adoption of this standard did not have a material effect on the Company’s financial statements as reflected herein. The carrying amounts of cash, prepaid expenses and accrued expenses reported on the balance sheet are estimated by management to approximate fair value primarily due to the short term nature of the instruments. Basic and Diluted Loss Per Share The basic net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding. Diluted net loss per common share is computed by dividing the net loss adjusted on an “as if converted” basis, by the weighted average number of common shares outstanding plus potential dilutive securities. For the periods presented, potential dilutive securities had an anti-dilutive effect and were not included in the calculation of diluted net loss per common share. Stock-Based Compensation Under FASB ASC 718-10-30-2, all share-based payments to employees, including grants of employee stock options, to be recognized in the income statement based on their fair values. Pro forma disclosure is no longer an alternative. The Company’s stock based compensation consisted of the following during the years ended December 31, 2017 and 2016, respectively: December 31, December 31, 2017 2016 Common stock issued for services $ 84,600 $ 70,621 Warrants issued for services, related parties 102,364 25,030 Warrants issued for services 9,617 14,739 Common stock issued for services on terminated offering 586,823 - Total stock based compensation $ 783,404 $ 110,390 Revenue Recognition Sales on fixed price contracts are recorded when services are earned, the earnings process is complete or substantially complete, and the revenue is measurable and collectability is reasonably assured. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded. The Company defers any revenue from sales in which payment has been received, but the earnings process has not occurred. Sales commenced on July 5, 2017 with the termination of our joint venture and are recognized upon shipment of goods, which are typically paid for at the time of order. Advertising and Promotion All costs associated with advertising and promoting products are expensed as incurred. These expenses were $64,108 and $82,246 for the years ended December 31, 2017 and 2016, respectively. Income Taxes Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided for significant deferred tax assets when it is more likely than not, that such asset will not be recovered through future operations. Uncertain Tax Positions In accordance with ASC 740, “Income Taxes” (“ASC 740”), the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be capable of withstanding examination by the taxing authorities based on the technical merits of the position. These standards prescribe a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. These standards also provide guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. Various taxing authorities periodically audit the Company’s income tax returns. These audits include questions regarding the Company’s tax filing positions, including the timing and amount of deductions and the allocation of income to various tax jurisdictions. In evaluating the exposures connected with these various tax filing positions, including state and local taxes, the Company records allowances for probable exposures. A number of years may elapse before a particular matter, for which an allowance has been established, is audited and fully resolved. The Company has not yet undergone an examination by any taxing authorities. The assessment of the Company’s tax position relies on the judgment of management to estimate the exposures associated with the Company’s various filing positions. Recently Issued Accounting Pronouncements In May 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) 2017-09 , Compensation — Stock Compensation (Topic 718): Scope of Modification Accounting. ASU 2017-9 In January 2017, the FASB issued ASU 2017-04, Intangibles – Goodwill and Other (Topic 350) In January 2017, the FASB issued ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business No other new accounting pronouncements, issued or effective during the year ended December 31, 2017, have had or are expected to have a significant impact on the Company’s financial statements.

Going Concern

Going Concern	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Notes to Financial Statements
Note 2 - Going Concern	As shown in the accompanying financial statements, the Company has no revenues, incurred net losses from operations resulting in an accumulated deficit of $15,762,488, and had negative working capital of ($1,934,048) at March 31, 2018. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The Company is currently seeking additional sources of capital to fund short term operations. The Company, however, is dependent upon its ability to secure equity and/or debt financing and there are no assurances that the Company will be successful; therefore, without sufficient financing it would be unlikely for the Company to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of any uncertainty as to the Company’s ability to continue as a going concern. The financial statements also do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.	As shown in the accompanying financial statements, the Company has no revenues, incurred net losses from operations resulting in an accumulated deficit of $16,328,812, and had negative working capital of ($2,616,204) at December 31, 2017. These factors raise substantial doubt about the Company’s ability to continue as a going concern. Management is actively pursuing new products and services to begin generating revenues. In addition, the Company is currently seeking additional sources of capital to fund short term operations. The Company, however, is dependent upon its ability to secure equity and/or debt financing and there are no assurances that the Company will be successful; therefore, without sufficient financing it would be unlikely for the Company to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of any uncertainty as to the Company’s ability to continue as a going concern. The financial statements also do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

Related Party

Related Party	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Notes to Financial Statements
Note 3 - Related Party	Accounts Payable The Company owed $39,116 and $40,195 as of March 31, 2018 and December 31, 2017, respectively, to entities owned by the Chairman of the Board of Directors. The amounts are related to patent costs and reimbursable expenses paid by the Chairman on behalf of the Company. The Company owed $713 as of March 31, 2018 and December 31, 2017, to the Company’s CEO for reimbursable expenses. The Company owed $1,075 and $478 as of March 31, 2018 and December 31, 2017, respectively, amongst members of the Company’s Board of Directors for reimbursable expenses.	Other Receivable The Company advanced a total of $48,778 to its joint venture partner, Premier Biomedical Pain Management Solutions, LLC, and was subsequently repaid a total of $44,604 on July 5, 2017 with the termination of the joint venture, resulting in a loss of $6,232, consisting of the original investment of $2,058 and the loss on this receivable of $4,174. Accounts Payable The Company owed $40,195 and $46,016 as of December 31, 2017 and 2016, respectively, to entities owned by the Chairman of the Board of Directors. The amounts are related to patent costs paid by the Chairman on behalf of the Company. The Company owed $713 and $306 as of December 31, 2017 and 2016, respectively, to the Company’s CEO for reimbursable expenses. The Company owed $478 and $6,167 as of December 31, 2017 and 2016, respectively, amongst members of the Company’s Board of Directors for reimbursable expenses. Notes Payable On July 6, 2015, the Company received an unsecured loan in the amount of $10,000, due on demand, bearing interest at a simple interest rate of 8%, from the Company’s CEO. The principal and interest was repaid in full in November of 2017. On July 6, 2015, the Company received an unsecured loan in the amount of $10,000, due on demand, bearing interest at a simple interest rate of 8%, from the Company’s Chairman of the Board. The principal and interest was repaid in full in November of 2017. On July 6, 2015, the Company received an unsecured loan in the amount of $10,000, due on demand, bearing interest at a simple interest rate of 8%, from one of the Company’s Directors. The principal and interest was repaid in full in November of 2017. Preferred Stock Issuances for Exercise of Preferred Stock Warrants On January 29, 2016, the Company issued 1,000,000 shares of series A preferred stock pursuant to the exercise of warrants by the Company’s CEO at $0.001 per share for total proceeds of $1,000. On January 29, 2016, the Company issued 1,000,000 shares of series A preferred stock pursuant to the exercise of warrants by the Company’s Chairman of the Board at $0.001 per share for total proceeds of $1,000. Common Stock Warrants Exercised On November 22, 2017, the Company issued 7,000,000 shares of common stock pursuant to the exercise of warrants by the Company’s CEO at $0.00001 per share for total proceeds of $70. On October 19, 2016, the Company issued 4,000,000 shares of common stock pursuant to the exercise of warrants by the Company’s CEO at $0.00001 per share for total proceeds of $40. On October 19, 2016, the Company issued 4,000,000 shares of common stock pursuant to the exercise of warrants by the Company’s Chairman of the Board at $0.00001 per share for total proceeds of $40. Common Stock Warrants Granted On December 22, 2017, the Company granted warrants to the following officers and directors, which will allow them to purchase shares of our common stock in the amounts indicated: William Hartman (8,500,000 shares); Mitchell Felder (8,500,000 shares), Heidi Carl (6,000,000 shares), John Borza (7,250,000 shares), Jay Rosen (1,000,000 shares), Patricio Reyes (4,000,000 shares) and John Pauly (2,000,000 shares). The exercise price of the foregoing warrants is five cents ($0.005) per share. The warrants are exercisable over seven (7) years. The total fair value of the 37,250,000 common stock warrants using the Black-Scholes option-pricing model is $102,364, or $0.00275 per share, based on a volatility rate of 195%, a risk-free interest rate of 2.01% and an expected term of 3.5 years, and was expensed upon issuance. Common Stock Issuances for Settlement of Accounts Payments On March 28, 2016, upon the resignation of Richard Najarian as one of the members of our Board of Directors, the Company issued 600,000 shares of common stock to Mr. Najarian in settlement of $13,765 of outstanding expense reimbursements. The total fair value of the common stock was $9,120 based on the closing price of the Company’s common stock on the date of grant.

Subsidiary Formation

Subsidiary Formation	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Notes to Financial Statements
Note 7 - Subsidiary Formation	On September 14, 2017, we formed Premier Biomedical Pain Relief Meds, LLC as a wholly-owned Nevada limited liability company. On January 1, 2018, we contributed our pain management assets to this entity and continued our pain management operations within this new subsidiary.	On January 1, 2018, we transferred the assets of our pain relief operations to Premier Biomedical Pain Relief Meds, LLC, a wholly-owned subsidiary formed on September 14, 2017.

Patent Rights and Applications

Patent Rights and Applications	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Notes to Financial Statements
Note 4 - Patent Rights and Applications	The Company amortizes its patent rights and applications on a straight line basis over the expected useful technological or economic life of the patents, which is typically 17 years from the legal approval of the patent applications when there is probable future economic benefits associated with the patent. The Company has elected to expense all of their patent rights and application costs due to difficulties associated with having to prove the value of their future economic benefits. All patent applications are currently pending and the Company has no patents that have yet been approved. It is the Company’s policy that it performs reviews of the carrying value of its patent rights and applications on an annual basis. On March 4, 2015, we entered into a Patent License Agreement (“PLA”) with the University of Texas at El Paso (“UTEP”) regarding our joint research and development of CTLA-4 Blockade with Metronomic Chemotherapy for the Treatment of Breast Cancer. This is the first PLA with UTEP following our Collaborative Agreement with them dated May 9, 2012, and memorializes the joint ownership of the applicable patent and the financial and other terms related thereto. On June 19, 2015, we entered into Amendment No. 1 to this Agreement, pursuant to which we explicitly included Provisional Patent Application No. 62/161,116 entitled, “Anti-CTLA-4 Blockade” (the “Application”) under the definition of “Patent Rights” as set forth in the PLA. The Application was filed with the United States Patent and Trademarks Office on May 13, 2015; the underlying technology was invented by Robert Kirken and Georgialina Rodriguez, and is solely-owned by The Board of Regents of The University of Texas System.	The Company amortizes its patent rights and applications on a straight line basis over the expected useful technological or economic life of the patents, which is typically 17 years from the legal approval of the patent applications when there is probable future economic benefits associated with the patent. The Company has elected to expense all of their patent rights and application costs due to difficulties associated with having to prove the value of their future economic benefits. All patent applications are currently pending and the Company has no patents that have yet been approved. It is the Company’s policy that it performs reviews of the carrying value of its patent rights and applications on an annual basis. On March 4, 2015, we entered into a Patent License Agreement (“PLA”) with the University of Texas at El Paso (“UTEP”) regarding our joint research and development of CTLA-4 Blockade with Metronomic Chemotherapy for the Treatment of Breast Cancer. This is the first PLA with UTEP following our Collaborative Agreement with them dated May 9, 2012, and memorializes the joint ownership of the applicable patent and the financial and other terms related thereto. On June 19, 2015, we entered into Amendment No. 1 to this Agreement, pursuant to which we explicitly included Provisional Patent Application No. 62/161,116 entitled, “Anti-CTLA-4 Blockade” (the “Application”) under the definition of “Patent Rights” as set forth in the PLA. The Application was filed with the United States Patent and Trademarks Office on May 13, 2015; the underlying technology was invented by Robert Kirken and Georgialina Rodriguez, and is solely-owned by The Board of Regents of The University of Texas System.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Notes to Financial Statements
Note 5 - Fair Value of Financial Instruments	Under FASB ASC 820-10-5, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (an exit price). The standard outlines a valuation framework and creates a fair value hierarchy in order to increase the consistency and comparability of fair value measurements and the related disclosures. Under GAAP, certain assets and liabilities must be measured at fair value, and FASB ASC 820-10-50 details the disclosures that are required for items measured at fair value. The Company has certain financial instruments that must be measured under the new fair value standard. The Company’s financial assets and liabilities are measured using inputs from the three levels of the fair value hierarchy. The three levels are as follows: Level 1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Level 2 - Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs). Level 3 - Unobservable inputs that reflect our assumptions about the assumptions that market participants would use in pricing the asset or liability. The following schedule summarizes the valuation of financial instruments at fair value on a recurring basis in the balance sheets as of March 31, 2018 and December 31, 2017, respectively: Fair Value Measurements at March 31, 2018 Level 1 Level 2 Level 3 Assets Cash $ 79,221 $ - $ - Total assets 79,221 - - Liabilities Convertible notes payable 154,778 Derivative liabilities - - 1,574,343 Total liabilities - 154,778 1,574,343 $ 79,221 $ (154,778 ) $ (1,574,343 ) Fair Value Measurements at December 31, 2017 Level 1 Level 2 Level 3 Assets Cash $ 83,704 $ - $ - Total assets 83,704 - - Liabilities Convertible note payable, net of discounts - 169,990 - Derivative liabilities - - 2,255,781 Total liabilities - 169,990 2,255,781 $ 83,704 $ (169,990 ) $ (2,255,781 ) The fair values of our related party debts are deemed to approximate book value, and are considered Level 2 inputs as defined by ASC Topic 820-10-35. There were no transfers of financial assets or liabilities between Level 1, Level 2 and Level 3 inputs for the three months ended March 31, 2018 or the year ended December 31, 2017.	Under FASB ASC 820-10-5, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (an exit price). The standard outlines a valuation framework and creates a fair value hierarchy in order to increase the consistency and comparability of fair value measurements and the related disclosures. Under GAAP, certain assets and liabilities must be measured at fair value, and FASB ASC 820-10-50 details the disclosures that are required for items measured at fair value. The Company has certain financial instruments that must be measured under the new fair value standard. The Company’s financial assets and liabilities are measured using inputs from the three levels of the fair value hierarchy. The three levels are as follows: Level 1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Level 2 - Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs). Level 3 - Unobservable inputs that reflect our assumptions about the assumptions that market participants would use in pricing the asset or liability. The following schedule summarizes the valuation of financial instruments at fair value on a recurring basis in the balance sheets as of December 31, 2017 and 2016, respectively: Fair Value Measurements at December 31, 2017 Level 1 Level 2 Level 3 Assets Cash $ 83,704 $ - $ - Total assets 83,704 - - Liabilities Convertible note payable, net of discounts - 169,990 - Derivative liabilities - - 2,255,781 Total liabilities - 169,990 2,255,781 $ 83,704 $ (169,990 ) $ (2,255,781 ) Fair Value Measurements at December 31, 2016 Level 1 Level 2 Level Assets Cash $ 22,437 $ - $ - Total assets 22,437 - - Liabilities Convertible note payable, net of discounts - 153,024 - Notes payable, related parties 30,000 - Derivative liabilities - - 221,822 Total liabilities - 183,024 221,822 $ 22,437 $ (183,024 ) $ (221,822 ) The fair values of our related party debts are deemed to approximate book value, and are considered Level 2 inputs as defined by ASC Topic 820-10-35. There were no transfers of financial assets or liabilities between Level 1, Level 2 and Level 3 inputs for the years ended December 31, 2017 or the year ended December 31, 2016.

Convertible Notes Payable

Convertible Notes Payable	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Notes to Financial Statements
Note 8 - Convertible Notes Payable	Convertible notes payable consist of the following at March 31, 2018 and December 31, 2017, respectively: March 31, December 31, 2018 2017 On March 1, 2018, the Company received proceeds of $30,000 in exchange for an 8% interest bearing; unsecured convertible promissory note maturing on May 31, 2018 (“First Red Diamond Note”). The note is convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date. $ 30,000 $ - On March 1, 2018, the Company received proceeds of $30,000 in exchange for an 8% interest bearing; unsecured convertible promissory note maturing on May 31, 2018 (“First SEG-RedaShex Note”). The note is convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date. 30,000 - On October 30, 2017, the Company received proceeds of $50,000 in exchange for an 8% interest bearing; unsecured convertible promissory note maturing on January 31, 2018 (“Second Diamond Rock Note”). The note is convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date. Currently in default. 50,000 50,000 On October 30, 2017, the Company received proceeds of $50,000 in exchange for an 8% interest bearing; unsecured convertible promissory note maturing on January 31, 2018 (“Second SEG Note”). The note is convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date. A total of $10,000 of principal was converted into 5,208,333 shares of common stock on October 31, 2017, and the remaining $40,000 of principal was converted into 26,559,426 shares of common stock on January 29, 2018. - 40,000 On August 8, 2017, the Company entered into an exchange agreement with Diamond Rock, LLC whereby they exchanged (i) the 13,333,334 Series A Warrants purchased in the First Closing, (ii) the 13,333,334 Series B Warrants purchased in the First Closing, and (iii) the 10,101,011 shares of common stock purchased in the Second Closing (the “Exchange Securities”) for a $50,000 convertible note (“First Diamond Rock Note”) issued by the Company, bearing interest at 8% interest and maturing on November 30, 2017. The notes are convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date. A total of $15,000 of principal was converted into an aggregate of 7,812,500 shares of common stock at various dates between November 6, 2017 and November 13, 2017. Currently in default. 35,000 35,000 On August 8, 2017, the Company entered into an exchange agreement with The Special Equities Group, LLC whereby they exchanged (i) the 13,333,334 Series A Warrants purchased in the First Closing, (ii) the 13,333,334 Series B Warrants purchased in the First Closing, and (iii) the 10,101,011 shares of common stock purchased in the Second Closing (the “Exchange Securities”) for a $50,000 convertible note (“First SEG Note”) issued by the Company, bearing interest at 8% interest and maturing on November 30, 2017. The notes are convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date. Currently in default. 50,000 50,000 On August 8, 2017, the Company entered into an exchange agreement with RDW Capital, LLC whereby they exchanged (i) the 13,333,334 Series A Warrants purchased in the First Closing, (ii) the 13,333,334 Series B Warrants purchased in the First Closing, and (iii) the 10,101,011 shares of common stock purchased in the Second Closing (the “Exchange Securities”) for a $50,000 convertible note (“First RDW Note”) issued by the Company, bearing interest at 8% interest and maturing on November 30, 2017. The notes are convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date. A total of $25,000 of principal was converted into 13,157,895 shares of common stock on October 31, 2017, and the remaining $25,000 of principal was converted into 19,230,769 shares of common stock on January 3, 2018. - 25,000 Total convertible notes payable, currently in default 195,000 200,000 Less unamortized derivative discounts: 40,222 30,010 Convertible notes payable 154,778 169,990 Less: current portion 154,778 169,990 Convertible notes payable, less current portion $ - $ - The Company recognized interest expense for the three months ended March 31, 2018 and 2017, respectively, as follows: March 31, March 31, 2018 2017 Interest on convertible notes $ 3,285 $ 2,691 Interest on related party loans 1,800 600 Derivative discounts 60,860 149,456 Total interest expense $ 64,145 $ 152,747	Convertible notes payable consist of the following at December 31, 2017 and 2016, respectively: December 31, December 31, 2017 2016 On October 30, 2017, the Company received proceeds of $50,000 in exchange for an 8% interest bearing; unsecured convertible promissory note maturing on January 31, 2018 (“Second Diamond Rock Note”). The note is convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date. Currently in default. $ 50,000 $ - On October 30, 2017, the Company received proceeds of $50,000 in exchange for an 8% interest bearing; unsecured convertible promissory note maturing on January 31, 2018 (“Second SEG Note”). The note is convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date. A total of $10,000 of principal was converted into 5,208,333 shares of common stock on October 31, 2017. Currently in default. 40,000 - On October 30, 2017, the Company received proceeds of $50,000 in exchange for an 8% interest bearing; unsecured convertible promissory note maturing on January 31, 2018 (“Second RDW Note”). The note is convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date. A total of $50,000 of principal was converted into an aggregate of 31,015,038 shares of common stock at various dates between November 8, 2017 and December 26, 2017. - - On August 8, 2017, the Company entered into an exchange agreement with Diamond Rock, LLC whereby they exchanged (i) the 13,333,334 Series A Warrants purchased in the First Closing, (ii) the 13,333,334 Series B Warrants purchased in the First Closing, and (iii) the 10,101,011 shares of common stock purchased in the Second Closing (the “Exchange Securities”) for a $50,000 convertible note (“First Diamond Rock Note”) issued by the Company, bearing interest at 8% interest and maturing on November 30, 2017. The notes are convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date. A total of $15,000 of principal was converted into an aggregate of 7,812,500 shares of common stock at various dates between November 6, 2017 and November 13, 2017. Currently in default. 35,000 - On August 8, 2017, the Company entered into an exchange agreement with The Special Equities Group, LLC whereby they exchanged (i) the 13,333,334 Series A Warrants purchased in the First Closing, (ii) the 13,333,334 Series B Warrants purchased in the First Closing, and (iii) the 10,101,011 shares of common stock purchased in the Second Closing (the “Exchange Securities”) for a $50,000 convertible note (“First SEG Note”) issued by the Company, bearing interest at 8% interest and maturing on November 30, 2017. The notes are convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date. Currently in default. 50,000 - On August 8, 2017, the Company entered into an exchange agreement with RDW Capital, LLC whereby they exchanged (i) the 13,333,334 Series A Warrants purchased in the First Closing, (ii) the 13,333,334 Series B Warrants purchased in the First Closing, and (iii) the 10,101,011 shares of common stock purchased in the Second Closing (the “Exchange Securities”) for a $50,000 convertible note (“First RDW Note”) issued by the Company, bearing interest at 8% interest and maturing on November 30, 2017. The notes are convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date. A total of $25,000 of principal was converted into 13,157,895 shares of common stock on October 31, 2017. Currently in default. 25,000 - On October 10, 2016, the Company issued a 10% interest bearing; unsecured convertible promissory note with a face value of $300,000 (“Seventh Redwood Note”), which matures on October 10, 2017, pursuant to a Warrant Purchase Agreement by and among Redwood Management, LLC, the Company and Typenex. Pursuant to this agreement, Redwood purchased the warrants from Typenex, and Typenex provided a Satisfaction of Judgment and Release of Garnishment to release the Writ of Garnishment Typenex had placed on our transfer agent. Redwood paid installment payments to Typenex in the aggregate amount of $300,000, which were completed on, or about November 10, 2016. The principal and interest of the Seventh Redwood Note is convertible into shares of common stock at the discretion of the note holder at a price equal to the greater of (i) 60% of the lowest traded price over the 15 days prior to conversion or (ii) a fixed $0.00005 per share. The note carries liquidated damages of $1,000 per day for failure to provide certificates, and compensation for Buy-In on failure to timely deliver certificates. Principal and interest is due upon default at 50% of the lowest traded price over the previous fifteen (15) days, and an additional interest rate equal to the lesser of 2% per month (24% per annum) or the maximum rate per applicable law. This settled the dispute with Typenex. A total of $308,750, consisting of $300,000 of principal and $8,750 of interest, was converted into 135,596,882 shares of common stock on various dates between November 21, 2016 and February 24, 2017. $ - $ 275,000 On March 11, 2016, the Company received net proceeds of $90,000 in exchange for a 10% interest bearing; unsecured convertible promissory note with a face value of $105,000 (“Fifth Redwood Note”), which matures on December 11, 2016. The principal and interest is convertible into shares of common stock at the discretion of the note holder at a price equal to the greater of (i) 60% of the lowest traded price over the 15 days prior to conversion or (ii) a fixed $0.00005 per share. The note carries liquidated damages of $1,000 per day for failure to provide certificates, and compensation for Buy-In on failure to timely deliver certificates. Principal and interest is due upon default at 50% of the lowest traded price over the previous fifteen (15) days, and an additional interest rate equal to the lesser of 2% per month (24% per annum) or the maximum rate per applicable law. A total of $120,517, consisting of $105,000 of principal and $15,517 of interest, was converted into an aggregate of 47,820,025 shares of common stock at various dates between November 8, 2016 and March 13, 2017. - 27,480 Total convertible notes payable, currently in default 200,000 302,480 Less unamortized derivative discounts: 30,010 149,456 Convertible notes payable 169,990 153,024 Less: current portion 169,990 153,024 Convertible notes payable, less current portion $ - $ - The Company recognized interest expense for the years ended December 31, 2017 and 2016, respectively, as follows: December 31, December 31, 2017 2016 Interest on convertible notes $ 8,531 $ 52,720 Interest on related party loans 2,010 2,400 Amortization of derivative discounts 340,961 551,149 Amortization of loan origination costs - 79,451 Amortization of beneficial conversion feature - 81,648 Amortization of OID - 36,914 Interest on judgment payable - 13,141 Total interest expense $ 351,502 $ 817,423 In accordance with ASC 470-20 Debt with Conversion and Other Options, the Company recorded total discounts of $221,515 and $652,433 for the variable conversion features of the convertible debts incurred during the years ended December 31, 2017 and 2016, respectively. The discounts, as recognized below, are being amortized to interest expense over the term of the debentures using the effective interest method. The Company recorded $340,961 and $749,162 of interest expense pursuant to the amortization of note discounts during the years ended December 31, 2017 and 2016, respectively. The Company recognized interest expense for the years ended December 31, 2017 and 2016, respectively, as follows: December 31, December 31, 2017 2016 Derivative discounts $ 221,515 $ 571,183 Original issue discounts - 23,750 Loan origination costs - 57,500 Total debt discounts $ 221,515 $ 652,433 All of the convertible debentures carry default provisions that place a “maximum share amount” on the note holders. The maximum share amount that can be owned as a result of the conversions to common stock by the note holders is 4.99% of the Company’s issued and outstanding shares. In accordance with ASC 815-15, the Company determined that the variable conversion feature and shares to be issued on the Redwood Notes represented embedded derivative features, and these are shown as derivative liabilities on the balance sheet. The Company calculated the fair value of the compound embedded derivatives associated with the convertible debentures utilizing a lattice model.

Derivative Liabilities

Derivative Liabilities	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Notes to Financial Statements
Note 10 - Derivative Liabilities	As discussed in Note 7 under Convertible Notes Payable, the Company issued debts that consist of the issuance of convertible notes with variable conversion provisions. The conversion terms of the convertible notes are variable based on certain factors, such as the future price of the Company’s common stock. The number of shares of common stock to be issued is based on the future price of the Company’s common stock. The number of shares of common stock issuable upon conversion of the promissory note is indeterminate. Due to the fact that the number of shares of common stock issuable could exceed the Company’s authorized share limit, the equity environment is tainted and all additional convertible debentures and warrants are included in the value of the derivative. Pursuant to ASC 815-15 Embedded Derivatives, the fair values of the variable conversion option and warrants and shares to be issued were recorded as derivative liabilities on the issuance date. The fair values of the Company’s derivative liabilities were estimated at the issuance date and are revalued at each subsequent reporting date, using a lattice model. The Company recognized current derivative liabilities of $1,574,343 and $2,255,781 at March 31, 2018 and December 31, 2017, respectively. The change in fair value of the derivative liabilities resulted in a gain of $700,240 and a loss of $5,100,091 for the three months ended March 31, 2018 and 2017, respectively, which has been reported within other expense in the statements of operations. The gain of $700,240 for the three months ended March 31, 2018 consisted of a gain of $718,750 due to the value attributable to the warrants and a net loss in market value of $18,510 on the convertible notes. The loss of $5,100,091 for the three months ended March 31, 2017 consisted of a loss of $4,945,782 due to the value attributable to the warrants, a loss of $147,088 in market value of the warrants and a net loss in market value of $7,221 on the convertible notes. The following is a summary of changes in the fair market value of the derivative liability during the three months ended March 31, 2018 and the year ended December 31, 2017, respectively: Derivative Liability Total Balance, December 31, 2016 $ 221,822 Increase in derivative value due to issuances of convertible promissory notes 221,515 Increase in derivative value attributable to tainted warrants 7,103,444 Decrease in derivative value attributable to exchange of warrants (3,766,437 ) Change in fair market value of derivative liabilities due to the mark to market adjustment (1,221,021 ) Debt conversions (303,542 ) Balance, December 31, 2017 $ 2,255,781 Increase in derivative value due to issuances of convertible promissory notes 71,072 Change in fair market value of derivative liabilities due to the mark to market adjustment (700,240 ) Debt conversions (52,270 ) Balance, March 31, 2018 $ 1,574,343 Key inputs and assumptions used to value the convertible debentures and warrants issued during the three months ended March 31, 2018: · Stock price ranging from $0.0063 to $0.0033 during these periods would fluctuate with projected volatility. · The notes convert with variable conversion prices and fixed conversion prices (tainted notes). · An event of default would occur -0-% of the time, increasing 2% per month to a maximum of 10%. · The projected annual volatility curve for each valuation period was based on the historical annual volatility of the company in the range of 146% - 313%. · The Company would redeem the notes -0-% of the time, increasing 1% per month to a maximum of 5%. · All notes are assumed to be extended at maturity by 2 years – the time required to convert out this volume of stock. · The holders of the securities would automatically convert midway through to maturity on a monthly basis based on ownership and trading volume limitations. · A change of control and fundamental transaction would occur initially -0-% of the time and increase monthly by -0-% to a maximum of -0-%. · The monthly trading volume would average $968,718 to $1,011,107 and would increase at 1% per month. · The stock price would fluctuate with the Company projected volatility using a random sampling (450,000 iterations for each valuation) from a normal distribution. The stock price of the underlying instrument is modelled such that it follows a geometric Brownian motion with constant drift and volatility. · The Holder would exercise the warrants after one trading day as they become exercisable (at issuance) at target prices of 3 to 5 times the projected reset price or higher. · Reset events were projected to occur by 3/31/18 and 12/31/18 – the reset provision ends 3/30/19 and the option expires 3/30/20. · The stock price would fluctuate with an annual volatility. The projected annual volatility curve for each valuation period was based on the historical annual volatility of the company and the term remaining in the range 253% - 191%. · The Holder would exercise the warrant at maturity in 2020 if the stock price was above the reset exercise price.	As discussed in Note 8 under Convertible Notes Payable, the Company issued debts that consist of the issuance of convertible notes with variable conversion provisions. The conversion terms of the convertible notes are variable based on certain factors, such as the future price of the Company’s common stock. The number of shares of common stock to be issued is based on the future price of the Company’s common stock. The number of shares of common stock issuable upon conversion of the promissory note is indeterminate. Due to the fact that the number of shares of common stock issuable could exceed the Company’s authorized share limit, the equity environment is tainted and all additional convertible debentures and warrants are included in the value of the derivative. Pursuant to ASC 815-15 Embedded Derivatives, the fair values of the variable conversion option and warrants and shares to be issued were recorded as derivative liabilities on the issuance date. The fair values of the Company’s derivative liabilities were estimated at the issuance date and are revalued at each subsequent reporting date, using a lattice model. The Company recognized current derivative liabilities of $2,255,781 and $221,822 at December 31, 2017 and 2016, respectively. The change in fair value of the derivative liabilities resulted in a loss of $2,115,986 and a loss of $26,048 for the years ended December 31, 2017 and 2016, respectively, which has been reported within other expense in the statements of operations. The loss of $2,115,986 for the year ended December 31, 2017 consisted of a loss of $7,103,444 attributable to the fair value of warrants, a gain of $3,766,437 due to the subsequent exchange of the warrants, a net loss in market value of $4,767 on the convertible notes and a net gain of $1,225,788 in market value of the warrants. The loss of $26,048 for the year ended December 31, 2016 consisted of a loss of $12,232 due to the value in excess of the face value of the convertible notes and a net loss in market value of $13,816 on the convertible notes. The following is a summary of changes in the fair market value of the derivative liability during the years ended December 31, 2017 and 2016, respectively: Derivative Liability Total Balance, December 31, 2015 $ 150,076 Increase in derivative value due to issuances of convertible promissory notes 583,415 Change in fair market value of derivative liabilities due to the mark to market adjustment 13,816 Debt conversions (525,485 ) Balance, December 31, 2016 $ 221,822 Increase in derivative value due to issuances of convertible promissory notes 221,515 Increase in derivative value attributable to tainted warrants 7,103,444 Decrease in derivative value attributable to exchange of warrants (3,766,437 ) Change in fair market value of derivative liabilities due to the mark to market adjustment (1,221,021 ) Debt conversions (303,542 ) Balance, December 31, 2017 $ 2,255,781 Key inputs and assumptions used to value the convertible debentures and warrants issued during the years ended December 31, 2017 and 2016: · Stock price ranging from $0.0081 to $0.0035 during these periods would fluctuate with projected volatility. · The notes convert with variable conversion prices and fixed conversion prices (tainted notes). · An event of default would occur -0-% of the time, increasing 2% per month to a maximum of 10%. · The projected annual volatility curve for each valuation period was based on the historical annual volatility of the company in the range of 141% - 232%. · The Company would redeem the notes -0-% of the time, increasing 1% per month to a maximum of 5%. · All notes are assumed to be extended at maturity by 2 years – the time required to convert out this volume of stock. · The holders of the securities would automatically convert midway through to maturity on a monthly basis based on ownership and trading volume limitations. · A change of control and fundamental transaction would occur initially -0-% of the time and increase monthly by -0-% to a maximum of -0-%. · The monthly trading volume would average $1,120,620 to $1,441,388 and would increase at 1% per month.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Notes to Financial Statements
Note 11 - Commitments and Contingencies	Collaborative Patent License Agreements On May 9, 2012, the Company entered into a Collaborative Agreement with the University of Texas at El Paso. Pursuant to the terms of the Agreement, the Company will work jointly with the University to develop a series of research and development programs around its sequential-dialysis technology in the areas of Alzheimer's Disease, Traumatic Brain Injury (TBI), Chronic Pain Syndrome, Fibromyalgia, Multiple Sclerosis, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease), Blood Sepsis, Cancer, Heart Attacks and Strokes. The programs will utilize the facilities at one or more of the University of Texas’ campuses. The Company will pay the University’s actual overhead for the projects, plus a negotiated facility and administration overhead expense, and 10% of all gross revenues associated with the sale, license and/or royalties of all products and treatment procedures directly affiliated with programs. Intellectual property jointly invented and developed as a result of the projects will be owned jointly by the University and the Company. The Agreement has an initial term of five (5) years, and is renewable upon mutual agreement of the parties. On March 4, 2015, we entered into a Patent License Agreement (PLA) with the University of Texas at El Paso (UTEP) regarding our joint research and development of CTLA-4 Blockade with Metronomic Chemotherapy for the Treatment of Breast Cancer. This is the first PLA with UTEP following our Collaborative Agreement with them dated May 9, 2012, and memorializes the joint ownership of the applicable patent and the financial and other terms related thereto. On June 19, 2015, we entered into Amendment No. 1 to this Agreement, pursuant to which we explicitly included Provisional Patent Application No. 62/161,116 entitled, “Anti-CTLA-4 Blockade” (the “Application”) under the definition of “Patent Rights” as set forth in the PLA. The Application was filed with the United States Patent and Trademarks Office on May 13, 2015; the underlying technology was invented by Robert Kirken and Georgialina Rodriguez, and is solely-owned by The Board of Regents of The University of Texas System. On October 31, 2017 we entered into an Agreement, Final Payment under Contract, and Release of all Claims, whereby we agreed to pay them a total of $326,336 arising out of the research and development agreements with an initial payment of $22,211, and monthly payments of varying amounts between $5,000 and $20,000 thereafter for twenty eight months until the balance is paid in full. Subject to the compliance of all terms, the intellectual property rights established and arising out of the collaborative agreements remain in full force and effect and the parties agreed to a mutual release upon the final contracted payment. The full amount of the liability has been recognized as an accounts payable as of the date of this filing.	Collaborative Patent License Agreements On May 9, 2012, the Company entered into a Collaborative Agreement with the University of Texas at El Paso. Pursuant to the terms of the Agreement, the Company will work jointly with the University to develop a series of research and development programs around its sequential-dialysis technology in the areas of Alzheimer’s Disease, Traumatic Brain Injury (TBI), Chronic Pain Syndrome, Fibromyalgia, Multiple Sclerosis, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig’s disease), Blood Sepsis, Cancer, Heart Attacks and Strokes. The programs will utilize the facilities at one or more of the University of Texas’ campuses. The Company will pay the University’s actual overhead for the projects, plus a negotiated facility and administration overhead expense, and 10% of all gross revenues associated with the sale, license and/or royalties of all products and treatment procedures directly affiliated with programs. Intellectual property jointly invented and developed as a result of the projects will be owned jointly by the University and the Company. The Agreement has an initial term of five (5) years, and is renewable upon mutual agreement of the parties. On March 4, 2015, we entered into a Patent License Agreement (PLA) with the University of Texas at El Paso (UTEP) regarding our joint research and development of CTLA-4 Blockade with Metronomic Chemotherapy for the Treatment of Breast Cancer. This is the first PLA with UTEP following our Collaborative Agreement with them dated May 9, 2012, and memorializes the joint ownership of the applicable patent and the financial and other terms related thereto. On June 19, 2015, we entered into Amendment No. 1 to this Agreement, pursuant to which we explicitly included Provisional Patent Application No. 62/161,116 entitled, “Anti-CTLA-4 Blockade” (the “Application”) under the definition of “Patent Rights” as set forth in the PLA. The Application was filed with the United States Patent and Trademarks Office on May 13, 2015; the underlying technology was invented by Robert Kirken and Georgialina Rodriguez, and is solely-owned by The Board of Regents of The University of Texas System. On October 31, 2017 we entered into an Agreement, Final Payment under Contract, and Release of all Claims, whereby we agreed to pay them a total of $326,336 arising out of the research and development agreements with an initial payment of $22,211, and monthly payments of varying amounts between $5,000 and $20,000 thereafter for twenty eight months until the balance is paid in full. Subject to the compliance of all terms, the intellectual property rights established and arising out of the collaborative agreements remain in full force and effect and the parties agreed to a mutual release upon the final contracted payment. The full amount of the liability has been recognized as an accounts payable as of the date of this filing.

Changes in Stockholders_ Equity

Changes in Stockholders’ Equity (Deficit)	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Notes to Financial Statements
Note 12 - Changes in Stockholders’ Equity (Deficit)	Convertible Preferred Stock, Series A The Company has 10,000,000 authorized shares of Preferred Stock, of which 2,000,000 shares of $0.001 par value Series A Convertible Preferred Stock (“Series A Preferred Stock”) have been designated. Each share of Series A Preferred Stock is convertible, at the option of the holder thereof, at any time after the issuance of such share into one (1) fully paid and non-assessable share of Common Stock. Each outstanding share of Series A Preferred Stock is entitled to one hundred (100) votes per share on all matters to which the shareholders of the Corporation are entitled or required to vote. The Company shall reserve and keep available out of its authorized but unissued shares of Common Stock such number of shares sufficient to effect the conversions. Common Stock The Company has one billion authorized shares of $0.00001 par value Common Stock, as increased pursuant to an amendment to the articles of incorporation on February 9, 2016. Common Stock Issuances for Debt Conversions On January 29, 2018, the Company issued 26,559,426 shares of common stock pursuant to the conversion of $40,000 of principal from the Second SEG Note. The note was converted in accordance with the conversion terms; therefore no gain or loss has been recognized. On January 3, 2018, the Company issued 19,230,769 shares of common stock pursuant to the conversion of $25,000 of principal from the First RDW Note. The note was converted in accordance with the conversion terms; therefore no gain or loss has been recognized. Common Stock Issuances on Subscriptions Payable On various dates from January 17, 2018 through February 13, 2018, the Company issued a total of 63,675,678 shares to The Special Equities Group and DiamondRock, LLC as compensation valued at $273,805 awarded on December 6, 2017.	Convertible Preferred Stock, Series A The Company has 10,000,000 authorized shares of Preferred Stock, of which 2,000,000 shares of $0.001 par value Series A Convertible Preferred Stock (“Series A Preferred Stock”) have been designated. Each share of Series A Preferred Stock is convertible, at the option of the holder thereof, at any time after the issuance of such share into one (1) fully paid and non-assessable share of Common Stock. Each outstanding share of Series A Preferred Stock is entitled to one hundred (100) votes per share on all matters to which the shareholders of the Corporation are entitled or required to vote. The Company shall reserve and keep available out of its authorized but unissued shares of Common Stock such number of shares sufficient to effect the conversions. Preferred Stock Issuances for Exercise of Preferred Stock Warrants, Related Parties (2016) On January 29, 2016, the Company issued 1,000,000 shares of series A preferred stock pursuant to the exercise of warrants by the Company’s CEO at $0.001 per share for total proceeds of $1,000. On January 29, 2016, the Company issued 1,000,000 shares of series A preferred stock pursuant to the exercise of warrants by the Company’s Chairman of the Board at $0.001 per share for total proceeds of $1,000. Common Stock The Company has one billion authorized shares of $0.00001 par value Common Stock, as increased pursuant to an amendment to the articles of incorporation on February 9, 2016. Securities Purchase Agreement (2017) On March 30, 2017, we entered into a Securities Purchase Agreement (the “Purchase Agreement”) by and between the Company and each of The Special Equities Group, LLC, RDW Capital LLC, and DiamondRock, LLC (each a “Purchaser” and collectively, the “Purchasers”) to sell our common stock and warrants at a fixed price. Pursuant to the Purchase Agreement, we received from the Purchasers an aggregate of $300,000, net of $15,000 of offering costs, in exchange for 40,000,002 shares of our common stock, warrants to purchase up to 40,000,002 shares of our common stock at an exercise price of $0.03 (“Series A Warrants”) and warrants to purchase up to 40,000,002 shares or our common stock at an exercise price of $0.05 (“Series B Warrants”). Both the Series A Warrants and Series B Warrants issued pursuant to the Purchase Agreement are exercisable immediately upon receipt and have a term of three years. In addition, the Purchaser is entitled to a one-time price reset on the purchase price of the common stock of each tranche to the lower of (i) $0.02 or (ii) a 50% discount to the average of the three lowest closing prices in the 20 trading days prior to the reset date, which is the earlier of (i) the 7 month anniversary of the closing of each tranche of this transaction or (ii) 20 trading days after the effectiveness of each tranche. The embedded value in this reset provision is disclosed further in Note 10. On May 30, 2017, the Purchasers bought additional shares of our common stock and warrants for $150,000 (the “Second Closing”), in exchange for 30,303,033 shares of our common stock, warrants to purchase up to 30,303,033 shares of our common stock at an exercise price of $0.03 (“Series A Warrants”) and warrants to purchase up to 30,303,033 shares or our common stock at an exercise price of $0.05 (“Series B Warrants”). Both the Series A Warrants and Series B Warrants issued pursuant to the Purchase Agreement are exercisable immediately upon receipt and have a term of three years. The per share purchase price of the Second Closing was the lesser of (i) $0.02, subject to certain adjustments for stock splits and other similar transactions, or (ii) 50% of the closing price on the trading day immediately prior to the date of sale. The total number of shares to be sold in the Second Closing were determined by dividing the total purchase amount of each closing (i.e., $150,000) by the per share purchase price. The Purchase Agreement limits each Purchaser to beneficial ownership of our common stock of no more than 9.99%. The Purchasers also have certain anti-dilution rights in the Purchase Agreement for a period of 12 months. These rights allow the Purchasers to exchange their shares of common stock received pursuant to the Purchase Agreement for additional shares on the same terms and conditions of a subsequent financing. On August 8, 2017, the Company and each of the three Purchasers also entered into exchange agreements whereby the Purchasers exchanged (i) the 13,333,334 Series A Warrants purchased in the First Closing, (ii) the 13,333,334 Series B Warrants purchased in the First Closing, and (iii) the 10,101,011 shares of common stock purchased in the Second Closing (the “Exchange Securities”) for a $50,000 convertible note (aggregate $150,000) issued by the Company, bearing interest at 8% interest and maturing on November 30, 2017. The notes are convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date. Registration Rights Agreement (2017) On March 30, 2017, we entered into a Registration Rights Agreement with the Purchasers in connection with the Purchase Agreement. In the Registration Rights Agreement, we agreed to prepare and file a registration statement with the Securities and Exchange Commission covering the resale of all of the shares of common stock sold to the Purchasers and the shares issuable upon exercise of the Series A Warrants and Series B Warrants. We agreed to file an initial registration statement as promptly as possible and have it declared effective no later than June 28, 2017 (or July 28, 2017 if the registration statement was reviewed by the Securities and Exchange Commission) and keep it continuously effective until the securities are sold or may be sold under Rule 144 of the Securities Act without volume or manner-of-sale restrictions. If all of the securities cannot be registered on one registration statement, we agreed to file subsequent registration statements to register the remaining securities as promptly as allowed. The registration statement was subsequently withdrawn on July 24, 2017 and the Purchase Agreement was amended on August 8, 2017 to change the terms of the third closing to an aggregate of $150,000 of convertible notes, bearing interest at 8%, convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date. Common Stock Issuances for Debt Conversions (2017) On various dates between October 31, 2017 and December 26, 2017, the Company issued a total of 57,193,766 shares of common stock pursuant to the conversion of an aggregate of $100,000 of principal, among the First and Second RDW, SEG and Diamond Rock Notes. The notes were converted in accordance with the conversion terms; therefore no gain or loss has been recognized. On various dates between January 10, 2017 and March 13, 2017, the Company issued a total of 142,148,242 shares of common stock pursuant to the conversion of an aggregate of $323,197, consisting of $302,480 of principal and $20,717 of interest, among the Second, Fifth and Seventh Redwood Notes. The notes were converted in accordance with the conversion terms; therefore no gain or loss has been recognized. Common Stock Issuances for Debt Conversions (2016) On various dates between April 6, 2016 and December 22, 2016, the Company issued a total of 152,837,041 shares of common stock pursuant to the conversion of an aggregate of $675,494, consisting of $653,771 of principal and $21,723 of interest, among the Seven Redwood Notes. The notes were converted in accordance with the conversion terms; therefore no gain or loss has been recognized. On April 19, 2016, the Company issued 3,159,944 shares of common stock pursuant to the conversion of $10,238 of principal on the First JMJ Note. The note was converted in accordance with the conversion terms; therefore no gain or loss has been recognized. On April 11, 2016, the Company issued 2,800,000 shares of common stock pursuant to the conversion of $9,744 of principal on the First JMJ Note. The note was converted in accordance with the conversion terms; therefore no gain or loss has been recognized. On March 17, 2016, the Company issued 4,400,000 shares of common stock pursuant to the conversion of $29,040 of principal on the First JMJ Financial Note. The note was converted in accordance with the conversion terms; therefore no gain or loss has been recognized. On March 2, 2016, the Company issued 2,000,000 shares of common stock pursuant to the conversion of $13,200 of principal on the First JMJ Financial Note. The note was converted in accordance with the conversion terms; therefore no gain or loss has been recognized. Common Stock Issuances on Stock Purchase Agreement (2017) On February 13, 2017, the Company drew down $8,000 on their Stock Purchase Agreement entered into on May 27, 2016, with Redwood and issued 2,000,000 shares of common stock pursuant to the Seventh Put Notice. On January 10, 2017, the Company drew down $10,323 on their Stock Purchase Agreement entered into on May 27, 2016, with Redwood and issued 3,147,110 shares of common stock pursuant to the Sixth Put Notice. Common Stock Issuances on Stock Purchase Agreement (2016) On December 13, 2016, the Company drew down $25,000 on their Stock Purchase Agreement entered into on May 27, 2016, with Redwood and issued 6,250,000 shares of common stock pursuant to the Fifth Put Notice. On November 22, 2016, the Company drew down $25,000 on their Stock Purchase Agreement entered into on May 27, 2016, with Redwood and issued 6,377,551 shares of common stock pursuant to the Fourth Put Notice. On November 8, 2016, the Company drew down $25,000 on their Stock Purchase Agreement entered into on May 27, 2016, with Redwood and issued 6,097,561 shares of common stock pursuant to the Third Put Notice. On August 12, 2016, the Company drew down $39,520 on their Stock Purchase Agreement entered into on May 27, 2016, with Redwood and issued 5,200,000 shares of common stock pursuant to the Second Put Notice. On July 21, 2016, the Company drew down $29,000 on their Stock Purchase Agreement entered into on May 27, 2016, with Redwood and issued 4,027,778 shares of common stock pursuant to the First Put Notice. Common Stock Issuances for Exercise of Common Stock Warrants (2017) On November 22, 2016, the Company issued 7,000,000 shares of common stock pursuant to the exercise of warrants by the Company’s CEO at $0.00001 per share for total proceeds of $70. Common Stock Issuances for Exercise of Common Stock Warrants (2016) On December 23, 2016, the Company issued 6,000,000 shares of common stock pursuant to the exercise of warrants by the Company’s CEO at $0.00001 per share for total proceeds of $60. On December 23, 2016, the Company issued 6,000,000 shares of common stock pursuant to the exercise of warrants by the Company’s Chairman of the Board at $0.00001 per share for total proceeds of $60. On October 19, 2016, the Company issued 4,000,000 shares of common stock pursuant to the exercise of warrants by the Company’s CEO at $0.00001 per share for total proceeds of $40. On October 19, 2016, the Company issued 4,000,000 shares of common stock pursuant to the exercise of warrants by the Company’s Chairman of the Board at $0.00001 per share for total proceeds of $40. On February 10, 2016, the Company issued 2,248,846 shares of common stock pursuant to the cashless exercise of 2,250,000 warrants by the Company’s securities attorney at $0.00001 per share. Common Stock Issuances for Debt Financing (2016) On February 10, 2016, the Company issued 600,000 shares of our common stock to a third-party for services rendered in connection with our recent financing transactions with Redwood Fund III, Ltd. The total fair value of the common stock was $9,600 based on the closing price of the Company’s common stock on the date of grant. On February 10, 2016, the Company issued 2,400,000 shares of our common stock to a third-party for services rendered in connection with our recent financing transactions with Redwood Fund III, Ltd. The total fair value of the common stock was $38,400 based on the closing price of the Company’s common stock on the date of grant. Common Stock Issuances for Settlement of Accounts Payments, Related Party (2016) On March 28, 2016, upon the resignation of Richard Najarian as one of the members of our Board of Directors, the Company issued 600,000 shares of common stock to Mr. Najarian in settlement of $13,765 of outstanding expense reimbursements. The total fair value of the common stock was $9,120 based on the closing price of the Company’s common stock on the date of grant. Common Stock Issuances for Services (2017) On December 6, 2017, we agreed to issue a total of 136,470,585 shares of our common stock to The Special Equities Group, LLC, RDW Capital, LLC and DiamondRock, LLC as compensation, of which a total of 72,794,907 shares were issued immediately with an aggregate fair value of $313,018 based on the closing price of the Company’s common stock on the date of grant, and the other 63,675,678 shares were subsequently issued on various dates between January 17, 2018 and February 13, 2018. The aggregate fair value of the shares issued subsequent to December 31, 2017 was $273,805. On August 25, 2017, we agreed to issue 9,000,000 shares of our common stock to a third-party for consulting services rendered. The shares were subsequently issued on December 1, 2017. The total fair value of the common stock was $84,600 based on the closing price of the Company’s common stock on the date of grant. Common Stock Issuances for Services (2016) On November 14, 2016, we issued 2,626,867 shares of our common stock to a third-party for legal services rendered. The total fair value of the common stock was $11,821 based on the closing price of the Company’s common stock on the date of grant. On February 12, 2016, we issued 600,000 shares of our common stock to a third-party for services rendered in connection with our recent financing transactions. The total fair value of the common stock was $10,800 based on the closing price of the Company’s common stock on the date of grant.

Income Taxes

Income Taxes	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Notes to Financial Statements
Note 15 - Income Taxes	The Company accounts for income taxes under FASB ASC 740-10, which requires use of the liability method. FASB ASC 740-10-25 provides that deferred tax assets and liabilities are recorded based on the differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes, referred to as temporary differences. For the three months ended March 31, 2018, and the year ended December 31, 2017, the Company incurred a net operating loss and, accordingly, no provision for income taxes has been recorded. In addition, no benefit for income taxes has been recorded due to the uncertainty of the realization of any tax assets. At March 31, 2018, and December 31, 2017, the Company had approximately $4,930,000 and $4,860,000 of federal net operating losses, respectively. The net operating loss carry forwards, if not utilized, will begin to expire in 2031. The components of the Company’s deferred tax asset are as follows: March 31, December 31, 2018 2017 Deferred tax assets: Net operating loss carry forwards $ 1,725,000 $ 1,701,000 Net deferred tax assets before valuation allowance $ 1,725,000 $ 1,701,000 Less: Valuation allowance (1,725,000 ) (1,701,000 ) Net deferred tax assets $ - $ - Based on the available objective evidence, including the Company’s history of losses, management believes it is more likely than not that the net deferred tax assets will not be fully realizable. Accordingly, the Company provided for a full valuation allowance against its net deferred tax assets at March 31, 2018, and December 31, 2017, respectively. A reconciliation between the amounts of income tax benefit determined by applying the applicable U.S. and state statutory income tax rate to pre-tax loss is as follows: March 31, December 31, 2018 2017 Federal and state statutory rate 21 % 35 % Change in valuation allowance on deferred tax assets (21) % (35) % In accordance with FASB ASC 740, the Company has evaluated its tax positions and determined there are no uncertain tax positions.	The Company accounts for income taxes under FASB ASC 740-10, which requires use of the liability method. FASB ASC 740-10-25 provides that deferred tax assets and liabilities are recorded based on the differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes, referred to as temporary differences. For the years ended December 31, 2017 and 2016, the Company incurred a net operating loss and, accordingly, no provision for income taxes has been recorded. In addition, no benefit for income taxes has been recorded due to the uncertainty of the realization of any tax assets. At December 31, 2017 and December 31, 2016, the Company had approximately $4,860,000 and $4,334,000 of federal net operating losses, respectively. The net operating loss carry forwards, if not utilized, will begin to expire in 2031. The components of the Company’s deferred tax asset are as follows: December 31, December 31, 2017 2016 Deferred tax assets: Net operating loss carry forwards $ 1,701,000 $ 1,516,900 Net deferred tax assets before valuation allowance $ 1,701,000 $ 1,516,900 Less: Valuation allowance (1,701,000 ) (1,516,900 ) Net deferred tax assets $ - $ - Based on the available objective evidence, including the Company’s history of losses, management believes it is more likely than not that the net deferred tax assets will not be fully realizable. Accordingly, the Company provided for a full valuation allowance against its net deferred tax assets at December 31, 2017 and 2016, respectively. A reconciliation between the amounts of income tax benefit determined by applying the applicable U.S. and State statutory income tax rate to pre-tax loss is as follows: December 31, December 31, 2017 2016 Federal and state statutory rate 35 % 35 % Change in valuation allowance on deferred tax assets (35 )% (35 )% In accordance with FASB ASC 740, the Company has evaluated its tax positions and determined there are no uncertain tax positions.

Subsequent Events

Subsequent Events	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Notes to Financial Statements
Note 16 - Subsequent Events	Securities Purchase Agreement On April 24, 2018, we received $60,000 from two investors from the sale of 8% interest bearing; unsecured convertible promissory notes maturing on May 31, 2018. The notes are convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date.	Securities Purchase Agreement On March 1, 2018, we received $60,000 from two investors from the sale of convertible notes. These investors have also committed to provide an additional $240,000 in the near future. The investors purchased convertible notes at the signing of a Securities Purchase Agreement for an aggregate amount of $60,000. The investors will buy additional convertible notes for an aggregate of $60,000 within five trading days of our filing a registration statement to cover the investors’ shares of common stock issuable upon conversion of the convertible notes. Within five trading days of the registration statement being declared effective, the investors will buy additional convertible notes for an aggregate of $180,000. Common Stock Issuances for Debt Conversions On January 29, 2018, the Company issued 26,559,426 shares of common stock pursuant to the conversion of $40,000 of principal from the Second SEG Note. The note was converted in accordance with the conversion terms; therefore no gain or loss has been recognized. On January 3, 2018, the Company issued 19,230,769 shares of common stock pursuant to the conversion of $25,000 of principal from the First RDW Note. The note was converted in accordance with the conversion terms; therefore no gain or loss has been recognized. Common Stock Issuances on Subscriptions Payable On various dates from January 17, 2018 through February 13, 2018, the Company issued a total of 63,675,678 shares to The Special Equities Group and DiamondRock, LLC as compensation valued at $273,805 awarded on December 6, 2017. On January 10, 2017, the Company drew down $10,323 on their Stock Purchase Agreement entered into on May 27, 2016, with Redwood and issued 3,147,110 shares of common stock pursuant to the Sixth Put Notice.

Joint Venture

Joint Venture	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Note 6 - Joint Venture	On September 13, 2016, we entered into an operating agreement to form a pain management joint venture company with Advanced Technologies Solutions (ATS), a company based in San Diego, California and owned by Ronald T. LaBorde, a member of our Board of Directors. The joint venture company, Premier Biomedical Pain Management Solutions, LLC, a Nevada limited liability company (PBPMS), to develop and market natural and cannabis-based generalized, neuropathic, and localized pain relief treatment products. We owned 50% of PBPMS and ATS owned the other 50%, with 89% of the profits allocated to us and the remaining 11% of profits allocated to ATS. As part of the agreement with ATS, Mr. LaBorde was appointed a member of our Board of Directors. PBPMS was required to enter into separate license agreements with us and ATS for the use of technology previously developed by both companies. Intellectual property developed jointly by the parties will be the property of PBPMS. However, ATS and Mr. LaBorde could have developed inventions and intellectual property independently from PBPMS, and such inventions and intellectual property would have been the sole property of ATS or Mr. LaBorde. Pursuant to the terms of the PBPMS operating agreement, The Company was to tender 1,250,000 warrants, for the purchase of an equal number of shares of our common stock at a strike price of $0.05, pursuant to the license agreement between ATS and PBPMS. The Company and Mr. LaBorde did not execute the license agreement or issue these warrants, and on July 5, 2017, the Company terminated the joint venture agreement, resulting in a loss of $6,232. Our initial capital contribution to PBPMS was $25,000. ATS was to contribute (i) technical, labor, manufacturing information and know-how required to produce the initial product, an extended duration topical pain relief patch; (ii) $5,000 worth of primary ingredients; and (iii) $5,000 worth of other materials to produce the initial prototype pain relief patches. PBPMS was managed by a board of managers (PBPMS Board). The PBPMS Board consisted of William A. Hartman, our President and Chief Executive Officer and member of our Board of Directors, Ronald T. LaBorde, the Founder of ATS and member of our Board of Directors, Dr. Patricio Reyes, our Chief Technology Officer and member of our Board of Directors, and John Borza, our Vice-President and member of our Board of Directors. Decisions of the PBPMS Board require unanimous approval. The PBPMS operating agreement was subject to other common terms and ownership transfer restrictions, including a right of first refusal; however, the operating agreement and entity were dissolved upon the termination of the joint venture on July 5, 2017.

Notes Payable, Related Parties

Notes Payable, Related Parties	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Note 9 - Notes Payable, Related Parties	Notes payable, related parties consist of the following at December 31, 2017 and 2016, respectively: December 31, December 31, 2017 2016 On July 6, 2015, the Company received an unsecured loan in the amount of $10,000, due on demand, bearing interest at a simple interest rate of 8%, from the Company’s CEO. $ - $ 10,000 On July 6, 2015, the Company received an unsecured loan in the amount of $10,000, due on demand, bearing interest at a simple interest rate of 8%, from the Company’s Chairman of the Board. - 10,000 On July 6, 2015, the Company received an unsecured loan in the amount of $10,000, due on demand, bearing interest at a simple interest rate of 8%, from one of the Company’s Directors. - 10,000 Total notes payable, related parties - 30,000 Less: current portion - 30,000 Notes payable, related parties, less current portion $ - $ - The Company recorded interest expense in the amount of $2,010 and $2,400 for the years ended December 31, 2017 and 2016, respectively related to notes payable, related parties. A total of $32,010, consisting of $30,000 of principal and $2,010 of interest was repaid on various dates within November of 2017.

Series A Convertible Preferred

Series A Convertible Preferred Stock Warrants	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Note 13 - Series A Convertible Preferred Stock Warrants	Series A Convertible Preferred Stock Warrants Granted No series A preferred stock warrants were granted during the years ended December 31, 2017 and 2016. Series A Preferred Stock Warrants Cancelled No series A preferred stock warrants were cancelled during the years ended December 31, 2017 and 2016. Series A Preferred Stock Warrants Expired No series A preferred stock warrants were expired during the years ended December 31, 2017 and 2016. Series A Preferred Stock Warrants Exercised On January 29, 2016, the Company issued 1,000,000 shares of series A preferred stock pursuant to the exercise of warrants by the Company’s CEO at $0.001 per share for total proceeds of $1,000. On January 29, 2016, the Company issued 1,000,000 shares of series A preferred stock pursuant to the exercise of warrants by the Company’s Chairman of the Board at $0.001 per share for total proceeds of $1,000. No Series A Preferred Stock Warrants were outstanding at December 31, 2017.

Common Stock Warrants

Common Stock Warrants	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Note 14 - Common Stock Warrants	Common Stock Warrants Granted (2017) On December 22, 2017, the Company granted warrants to the following officers and directors, which will allow them to purchase shares of our common stock in the amounts indicated: William Hartman (8,500,000 shares); Mitchell Felder (8,500,000 shares), Heidi Carl (6,000,000 shares), John Borza (7,250,000 shares), Jay Rosen (1,000,000 shares), Patricio Reyes (4,000,000 shares) and John Pauly (2,000,000 shares). The exercise price of the foregoing warrants is five cents ($0.005) per share. The warrants are exercisable over seven (7) years. The total fair value of the 37,250,000 common stock warrants using the Black-Scholes option-pricing model is $102,364, or $0.00275 per share, based on a volatility rate of 195%, a risk-free interest rate of 2.01% and an expected term of 3.5 years, and was expensed upon issuance. On December 22, 2017, we also issued warrants to purchase a total of three million five hundred thousand (3,500,000) shares of our common stock amongst three members of our Scientific Advisory Board. The exercise price of the foregoing warrants is five cents ($0.005) per share. The warrants are exercisable over seven (7) years. The total fair value of the 3,500,000 common stock warrants using the Black-Scholes option-pricing model is $9,617, or $0.00275 per share, based on a volatility rate of 195%, a risk-free interest rate of 2.01% and an expected term of 3.5 years, and was expensed upon issuance. A total of $111,981 and $39,769 of warrants were amortized and expensed to professional fees as stock-based compensation during the years ended December 31, 2017 and 2016, respectively, including $102,364 and $25,030 during the years ended December 31, 2017 and 2016, respectively, related to warrants issued to related parties. Common Stock Warrants Cancelled (2016) A total of 351,455 warrants exercisable at the lesser of (i) $0.18, and (ii) 70% of the Market Price, which is the average of the three (3) lowest VWAPs, not less than a fixed floor of $0.0001, during the twenty (20) trading day period ending on the last complete trading day prior to the date the conversion notice is delivered, or 65% if that price is less than $0.10 per share was cancelled during the year ended December 31, 2016 pursuant to the settlement reached with Typenex. Common Stock Warrants Expired (2016) A total of 300,000 warrants exercisable at $0.96 per share expired during year ended December 31, 2016. Exercise of Common Stock Warrants (2016) On February 10, 2016, the Company issued 2,248,846 shares of common stock pursuant to the cashless exercise of 2,250,000 warrants by the Company’s securities attorney at $0.00001 per share. Exercise of Common Stock Warrants, Related Party (2017) On November 22, 2017, the Company issued 7,000,000 shares of common stock pursuant to the exercise of warrants by the Company’s CEO at $0.00001 per share for total proceeds of $70. Exercise of Common Stock Warrants, Related Party (2016) On December 23, 2016, the Company issued 6,000,000 shares of common stock pursuant to the exercise of warrants by the Company’s CEO at $0.00001 per share for total proceeds of $60. On December 23, 2016, the Company issued 6,000,000 shares of common stock pursuant to the exercise of warrants by the Company’s Chairman of the Board at $0.00001 per share for total proceeds of $60. On October 19, 2016, the Company issued 4,000,000 shares of common stock pursuant to the exercise of warrants by the Company’s CEO at $0.00001 per share for total proceeds of $40. On October 19, 2016, the Company issued 4,000,000 shares of common stock pursuant to the exercise of warrants by the Company’s Chairman of the Board at $0.00001 per share for total proceeds of $40. The following is a summary of information about the Common Stock Warrants outstanding at December 31, 2017. Shares Underlying Warrants Outstanding Shares Underlying Warrants Exercisable Range of Exercise Shares Underlying Warrants Weighted Average Remaining Contractual Weighted Average Exercise Shares Underlying Warrants Weighted Average Exercise Prices Outstanding Life Price Exercisable Price $0.00001 – $1.45 64,440,000 6.01 years $ 0.1194 64,440,000 $ 0.1194 The fair value of each warrant grant is estimated on the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions used for grants under the fixed option plan: December 31, December 31, 2017 2016 Average risk-free interest rates 1.75 % N/A Average expected life (in years) 9.22 N/A The Black-Scholes option pricing model was developed for use in estimating the fair value of short-term traded options that have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions including expected stock price volatility. Because the Company’s common stock warrants have characteristics significantly different from those of traded options and because changes in the subjective input assumptions can materially affect the fair value estimate, in management’s opinion the existing models do not necessarily provide a reliable single measure of the fair value of its common stock warrants. During the years ended December 31, 2017 and 2016 there were no warrants granted with an exercise price below the fair value of the underlying stock at the grant date. The weighted average fair value of warrants granted with exercise prices at the current fair value of the underlying stock was approximately $0.00275 per warrant granted during the year ended December 31, 2017. The following is a summary of activity of outstanding common stock warrants: Weighted Average Number of Exercise Shares Price Balance, December 31, 2015 53,591,455 $ 0.1463 Warrants cancelled (351,455 ) (0.18 ) Warrants expired (300,000 ) (0.96 ) Warrants exercised (22,250,000 ) (0.00001 ) Balance, December 31, 2016 30,690,000 $ 0.24407 Warrants granted 40,750,000 0.005 Warrants exercised (7,000,000 ) (0.00001 ) Balance, December 31, 2017 64,440,000 $ 0.1194 Exercisable, December 31, 2017 64,440,000 $ 0.1194

Basis of Presentation and Sig23

Basis of Presentation and Significant Accounting Policies (Policies)	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Basis Of Presentation And Significant Accounting Policies Policies
Basis of Presentation	The accompanying unaudited, condensed financial statements of Premier Biomedical, Inc. (“the Company”) have been prepared pursuant to rules and regulations of the Securities and Exchange Commission (“SEC”) and, therefore, do not include all information and footnote disclosures normally included in audited financial statements. However, these statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary for fair presentation of the information contained therein. It is suggested that these statements be read in conjunction with the financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017.
Nature of Business		Premier Biomedical, Inc. (“the Company”) was incorporated in the State of Nevada on May 10, 2010 (“Inception”). The Company was formed to develop and market medications and procedures that address a significant number of the most highly visible health issues currently affecting mankind. Our current focus is primarily on the development and distribution of our pain products. These statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary for fair presentation of the information contained therein.
Equity Method		Investee companies that are not consolidated, but over which the Company exercises significant influence, are accounted for under the equity method of accounting. Whether or not the Company exercises significant influence with respect to an Investee depends on an evaluation of several factors including, among others, representation on the Investee company’s board of directors and ownership level, which is generally a 20% to 50% interest in the voting securities of the Investee company. Under the equity method of accounting, an Investee company’s accounts are not reflected within the Company’s Balance Sheets and Statements of Operations; however, the Company’s share of the earnings or losses of the Investee company is reflected in the caption “Equity in losses of unconsolidated entity” in the Statements of Operations. The Company’s carrying value in an equity method Investee company is typically reflected in the caption “Investment in Joint Venture.” in the Company’s Balance Sheets. As of December 31, 2017, our share of losses from the investee company exceeded our basis, therefore the investment is not currently presented on the balance sheet. U.S. GAAP considers a change in reporting entity to include “changing specific subsidiaries that make up the group of entities for which consolidated financial statements are presented.” Circumstances may arise where a parent’s controlling financial interest (e.g., generally an ownership interest in excess of 50 percent of the outstanding voting stock) is reduced to a noncontrolling investment that still enables it to exercise significant influence over the operating and financial policies of the investee. A change that results from changed facts and circumstances (such as a partial sale of a subsidiary), where there was only one acceptable method of accounting prior to the change in circumstances (consolidation) and only one acceptable method of accounting after the change (equity method accounting), is not a change in reporting entity and is not be accounted for retrospectively. Accordingly, a change from a controlling interest to a noncontrolling investment accounted for under the equity method is accounted for prospectively from the date of change in control. When the Company’s carrying value in an equity method Investee company is reduced to zero, no further losses are recorded in the Company’s consolidated financial statements unless the Company guaranteed obligations of the Investee company or has committed additional funding. When the Investee company subsequently reports income, the Company will not record its share of such income until it equals the amount of its share of losses not previously recognized.
Use of Estimates	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents	We maintain cash balances in non-interest-bearing accounts, which do not currently exceed federally insured limits. For the purpose of the statements of cash flows, all highly liquid investments with an original maturity of three months or less are considered to be cash equivalents.	We maintain cash balances in non-interest-bearing accounts, which do not currently exceed federally insured limits. For the purpose of the statements of cash flows, all highly liquid investments with an original maturity of three months or less are considered to be cash equivalents.
Patent Rights and Applications	Patent rights and applications costs include the acquisition costs and costs incurred for the filing of patents. Patent rights and applications are amortized on a straight-line basis over the legal life of the patent rights beginning at the time the patents are approved. Patent costs for unsuccessful patent applications are expensed when the application is terminated.	Patent rights and applications costs include the acquisition costs and costs incurred for the filing of patents. Patent rights and applications are amortized on a straight-line basis over the legal life of the patent rights beginning at the time the patents are approved. Patent costs for unsuccessful patent applications are expensed when the application is terminated.
Fair Value of Financial Instruments	Under FASB ASC 820-10-05, the Financial Accounting Standards Board establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosures about fair value measurements. This Statement reaffirms that fair value is the relevant measurement attribute. The adoption of this standard did not have a material effect on the Company’s financial statements as reflected herein. The carrying amounts of cash, prepaid expenses and accrued expenses reported on the balance sheet are estimated by management to approximate fair value primarily due to the short term nature of the instruments.	Under FASB ASC 820-10-05, the Financial Accounting Standards Board establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosures about fair value measurements. This Statement reaffirms that fair value is the relevant measurement attribute. The adoption of this standard did not have a material effect on the Company’s financial statements as reflected herein. The carrying amounts of cash, prepaid expenses and accrued expenses reported on the balance sheet are estimated by management to approximate fair value primarily due to the short term nature of the instruments.
Basic and Diluted Loss Per Share	Basic earnings per share (“EPS”) are computed by dividing net income (the numerator) by the weighted average number of common shares outstanding for the period (the denominator). Diluted EPS is computed by dividing net income by the weighted average number of common shares and potential common shares outstanding (if dilutive) during each period. Potential common shares include stock options, warrants and restricted stock. The number of potential common shares outstanding relating to stock options, warrants and restricted stock is computed using the treasury stock method. The reconciliation of the denominators used to calculate basic EPS and diluted EPS for the three months ended March 31, 2018 and 2017 are as follows: For the Three Months Ended March 31, 2018 2017 Weighted average common shares outstanding – basic 718,803,900 401,283,532 Plus: Potentially dilutive common shares: Stock options and warrants 2,992,500 - Weighted average common shares outstanding – diluted 721,796,400 401,283,532 For the three months ended March 31, 2017, potential dilutive securities had an anti-dilutive effect and were not included in the calculation of diluted net loss per common share. Stock options and warrants excluded from the calculation of diluted EPS because their effect was anti-dilutive were 61,440,000 and 110,690,004 as of March 31, 2018 and 2017, respectively.	The basic net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding. Diluted net loss per common share is computed by dividing the net loss adjusted on an “as if converted” basis, by the weighted average number of common shares outstanding plus potential dilutive securities. For the periods presented, potential dilutive securities had an anti-dilutive effect and were not included in the calculation of diluted net loss per common share.
Stock-Based Compensation	Under FASB ASC 718-10-30-2, all share-based payments to employees, including grants of employee stock options, to be recognized in the income statement based on their fair values. Pro forma disclosure is no longer an alternative. The Company had no stock based compensation issuances during the three months ended March 31, 2018 and 2017.	Under FASB ASC 718-10-30-2, all share-based payments to employees, including grants of employee stock options, to be recognized in the income statement based on their fair values. Pro forma disclosure is no longer an alternative. The Company’s stock based compensation consisted of the following during the years ended December 31, 2017 and 2016, respectively: December 31, December 31, 2017 2016 Common stock issued for services $ 84,600 $ 70,621 Warrants issued for services, related parties 102,364 25,030 Warrants issued for services 9,617 14,739 Common stock issued for services on terminated offering 586,823 - Total stock based compensation $ 783,404 $ 110,390
Revenue Recognition	Sales on fixed price contracts are recorded when services are earned, the earnings process is complete or substantially complete, and the revenue is measurable and collectability is reasonably assured. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded. The Company defers any revenue from sales in which payment has been received, but the earnings process has not occurred. Sales commenced on July 5, 2017 with the termination of our joint venture and are recognized upon shipment of goods, which are typically paid for at the time of order.	Sales on fixed price contracts are recorded when services are earned, the earnings process is complete or substantially complete, and the revenue is measurable and collectability is reasonably assured. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded. The Company defers any revenue from sales in which payment has been received, but the earnings process has not occurred. Sales commenced on July 5, 2017 with the termination of our joint venture and are recognized upon shipment of goods, which are typically paid for at the time of order.
Advertising and Promotion	All costs associated with advertising and promoting products are expensed as incurred. These expenses were $9,925 and $67,216 for the three months ended March 31, 2018 and 2017, respectively.	All costs associated with advertising and promoting products are expensed as incurred. These expenses were $64,108 and $82,246 for the years ended December 31, 2017 and 2016, respectively.
Income Taxes	Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided for significant deferred tax assets when it is more likely than not, that such asset will not be recovered through future operations.	Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided for significant deferred tax assets when it is more likely than not, that such asset will not be recovered through future operations.
Uncertain Tax Positions	In accordance with ASC 740, “Income Taxes” (“ASC 740”), the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be capable of withstanding examination by the taxing authorities based on the technical merits of the position. These standards prescribe a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. These standards also provide guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. Various taxing authorities periodically audit the Company’s income tax returns. These audits include questions regarding the Company’s tax filing positions, including the timing and amount of deductions and the allocation of income to various tax jurisdictions. In evaluating the exposures connected with these various tax filing positions, including state and local taxes, the Company records allowances for probable exposures. A number of years may elapse before a particular matter, for which an allowance has been established, is audited and fully resolved. The Company has not yet undergone an examination by any taxing authorities. The assessment of the Company’s tax position relies on the judgment of management to estimate the exposures associated with the Company’s various filing positions.	In accordance with ASC 740, “Income Taxes” (“ASC 740”), the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be capable of withstanding examination by the taxing authorities based on the technical merits of the position. These standards prescribe a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. These standards also provide guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. Various taxing authorities periodically audit the Company’s income tax returns. These audits include questions regarding the Company’s tax filing positions, including the timing and amount of deductions and the allocation of income to various tax jurisdictions. In evaluating the exposures connected with these various tax filing positions, including state and local taxes, the Company records allowances for probable exposures. A number of years may elapse before a particular matter, for which an allowance has been established, is audited and fully resolved. The Company has not yet undergone an examination by any taxing authorities. The assessment of the Company’s tax position relies on the judgment of management to estimate the exposures associated with the Company’s various filing positions.
Recent Accounting Pronouncements	Effective January 1, 2018, the Company adopted ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts to perform pilot studies by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. For the comparative periods, revenue has not been adjusted and continues to be reported under ASC 605 — Revenue Recognition. Under ASC 605, revenue is recognized when the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) the performance of service has been rendered to a customer or delivery has occurred; (3) the amount of fee to be paid by a customer is fixed and determinable; and (4) the collectability of the fee is reasonably assured. There was no impact on the Company’s financial statements as a result of adopting Topic 606 for the three months ended March 31, 2018 and 2017, or the twelve months ended December 31, 2017. In May 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) 2017-09 , Compensation — Stock Compensation (Topic 718): Scope of Modification Accounting. ASU 2017-9 No other new accounting pronouncements, issued or effective during the three months ended March 31, 2018, have had or are expected to have a significant impact on the Company’s financial statements.	In May 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) 2017-09 , Compensation — Stock Compensation (Topic 718): Scope of Modification Accounting. ASU 2017-9 In January 2017, the FASB issued ASU 2017-04, Intangibles – Goodwill and Other (Topic 350) In January 2017, the FASB issued ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business No other new accounting pronouncements, issued or effective during the year ended December 31, 2017, have had or are expected to have a significant impact on the Company’s financial statements.

Basis of Presentation and Sig24

Basis of Presentation and Significant Accounting Policies (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Basis Of Presentation And Significant Accounting Policies Tables
Stock-Based Compensation	The reconciliation of the denominators used to calculate basic EPS and diluted EPS for the three months ended March 31, 2018 and 2017 are as follows: For the Three Months Ended March 31, 2018 2017 Weighted average common shares outstanding – basic 718,803,900 401,283,532 Plus: Potentially dilutive common shares: Stock options and warrants 2,992,500 - Weighted average common shares outstanding – diluted 721,796,400 401,283,532	December 31, December 31, 2017 2016 Common stock issued for services $ 84,600 $ 70,621 Warrants issued for services, related parties 102,364 25,030 Warrants issued for services 9,617 14,739 Common stock issued for services on terminated offering 586,823 - Total stock based compensation $ 783,404 $ 110,390

Fair Value of Financial Instr25

Fair Value of Financial Instruments (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Fair Value Of Financial Instruments Tables
Fair Value of Financial Instruments on Recurring Basis	The following schedule summarizes the valuation of financial instruments at fair value on a recurring basis in the balance sheets as of March 31, 2018 and December 31, 2017, respectively: Fair Value Measurements at March 31, 2018 Level 1 Level 2 Level 3 Assets Cash $ 79,221 $ - $ - Total assets 79,221 - - Liabilities Convertible notes payable 154,778 Derivative liabilities - - 1,574,343 Total liabilities - 154,778 1,574,343 $ 79,221 $ (154,778 ) $ (1,574,343 ) Fair Value Measurements at December 31, 2017 Level 1 Level 2 Level 3 Assets Cash $ 83,704 $ - $ - Total assets 83,704 - - Liabilities Convertible note payable, net of discounts - 169,990 - Derivative liabilities - - 2,255,781 Total liabilities - 169,990 2,255,781 $ 83,704 $ (169,990 ) $ (2,255,781 )	Fair Value Measurements at December 31, 2017 Level 1 Level 2 Level 3 Assets Cash $ 83,704 $ - $ - Total assets 83,704 - - Liabilities Convertible note payable, net of discounts - 169,990 - Derivative liabilities - - 2,255,781 Total liabilities - 169,990 2,255,781 $ 83,704 $ (169,990 ) $ (2,255,781 ) Fair Value Measurements at December 31, 2016 Level 1 Level 2 Level Assets Cash $ 22,437 $ - $ - Total assets 22,437 - - Liabilities Convertible note payable, net of discounts - 153,024 - Notes payable, related parties 30,000 - Derivative liabilities - - 221,822 Total liabilities - 183,024 221,822 $ 22,437 $ (183,024 ) $ (221,822 )

Convertible Notes Payable (Tabl

Convertible Notes Payable (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Convertible Notes Payable Tables
Summary of convertible note payable	March 31, December 31, 2018 2017 On March 1, 2018, the Company received proceeds of $30,000 in exchange for an 8% interest bearing; unsecured convertible promissory note maturing on May 31, 2018 (“First Red Diamond Note”). The note is convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date. $ 30,000 $ - On March 1, 2018, the Company received proceeds of $30,000 in exchange for an 8% interest bearing; unsecured convertible promissory note maturing on May 31, 2018 (“First SEG-RedaShex Note”). The note is convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date. 30,000 - On October 30, 2017, the Company received proceeds of $50,000 in exchange for an 8% interest bearing; unsecured convertible promissory note maturing on January 31, 2018 (“Second Diamond Rock Note”). The note is convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date. Currently in default. 50,000 50,000 On October 30, 2017, the Company received proceeds of $50,000 in exchange for an 8% interest bearing; unsecured convertible promissory note maturing on January 31, 2018 (“Second SEG Note”). The note is convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date. A total of $10,000 of principal was converted into 5,208,333 shares of common stock on October 31, 2017, and the remaining $40,000 of principal was converted into 26,559,426 shares of common stock on January 29, 2018. - 40,000 On August 8, 2017, the Company entered into an exchange agreement with Diamond Rock, LLC whereby they exchanged (i) the 13,333,334 Series A Warrants purchased in the First Closing, (ii) the 13,333,334 Series B Warrants purchased in the First Closing, and (iii) the 10,101,011 shares of common stock purchased in the Second Closing (the “Exchange Securities”) for a $50,000 convertible note (“First Diamond Rock Note”) issued by the Company, bearing interest at 8% interest and maturing on November 30, 2017. The notes are convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date. A total of $15,000 of principal was converted into an aggregate of 7,812,500 shares of common stock at various dates between November 6, 2017 and November 13, 2017. Currently in default. 35,000 35,000 On August 8, 2017, the Company entered into an exchange agreement with The Special Equities Group, LLC whereby they exchanged (i) the 13,333,334 Series A Warrants purchased in the First Closing, (ii) the 13,333,334 Series B Warrants purchased in the First Closing, and (iii) the 10,101,011 shares of common stock purchased in the Second Closing (the “Exchange Securities”) for a $50,000 convertible note (“First SEG Note”) issued by the Company, bearing interest at 8% interest and maturing on November 30, 2017. The notes are convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date. Currently in default. 50,000 50,000 On August 8, 2017, the Company entered into an exchange agreement with RDW Capital, LLC whereby they exchanged (i) the 13,333,334 Series A Warrants purchased in the First Closing, (ii) the 13,333,334 Series B Warrants purchased in the First Closing, and (iii) the 10,101,011 shares of common stock purchased in the Second Closing (the “Exchange Securities”) for a $50,000 convertible note (“First RDW Note”) issued by the Company, bearing interest at 8% interest and maturing on November 30, 2017. The notes are convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date. A total of $25,000 of principal was converted into 13,157,895 shares of common stock on October 31, 2017, and the remaining $25,000 of principal was converted into 19,230,769 shares of common stock on January 3, 2018. - 25,000 Total convertible notes payable, currently in default 195,000 200,000 Less unamortized derivative discounts: 40,222 30,010 Convertible notes payable 154,778 169,990 Less: current portion 154,778 169,990 Convertible notes payable, less current portion $ - $ -	Convertible notes payable consist of the following at December 31, 2017 and 2016, respectively: December 31, December 31, 2017 2016 On October 30, 2017, the Company received proceeds of $50,000 in exchange for an 8% interest bearing; unsecured convertible promissory note maturing on January 31, 2018 (“Second Diamond Rock Note”). The note is convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date. Currently in default. $ 50,000 $ - On October 30, 2017, the Company received proceeds of $50,000 in exchange for an 8% interest bearing; unsecured convertible promissory note maturing on January 31, 2018 (“Second SEG Note”). The note is convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date. A total of $10,000 of principal was converted into 5,208,333 shares of common stock on October 31, 2017. Currently in default. 40,000 - On October 30, 2017, the Company received proceeds of $50,000 in exchange for an 8% interest bearing; unsecured convertible promissory note maturing on January 31, 2018 (“Second RDW Note”). The note is convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date. A total of $50,000 of principal was converted into an aggregate of 31,015,038 shares of common stock at various dates between November 8, 2017 and December 26, 2017. - - On August 8, 2017, the Company entered into an exchange agreement with Diamond Rock, LLC whereby they exchanged (i) the 13,333,334 Series A Warrants purchased in the First Closing, (ii) the 13,333,334 Series B Warrants purchased in the First Closing, and (iii) the 10,101,011 shares of common stock purchased in the Second Closing (the “Exchange Securities”) for a $50,000 convertible note (“First Diamond Rock Note”) issued by the Company, bearing interest at 8% interest and maturing on November 30, 2017. The notes are convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date. A total of $15,000 of principal was converted into an aggregate of 7,812,500 shares of common stock at various dates between November 6, 2017 and November 13, 2017. Currently in default. 35,000 - On August 8, 2017, the Company entered into an exchange agreement with The Special Equities Group, LLC whereby they exchanged (i) the 13,333,334 Series A Warrants purchased in the First Closing, (ii) the 13,333,334 Series B Warrants purchased in the First Closing, and (iii) the 10,101,011 shares of common stock purchased in the Second Closing (the “Exchange Securities”) for a $50,000 convertible note (“First SEG Note”) issued by the Company, bearing interest at 8% interest and maturing on November 30, 2017. The notes are convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date. Currently in default. 50,000 - On August 8, 2017, the Company entered into an exchange agreement with RDW Capital, LLC whereby they exchanged (i) the 13,333,334 Series A Warrants purchased in the First Closing, (ii) the 13,333,334 Series B Warrants purchased in the First Closing, and (iii) the 10,101,011 shares of common stock purchased in the Second Closing (the “Exchange Securities”) for a $50,000 convertible note (“First RDW Note”) issued by the Company, bearing interest at 8% interest and maturing on November 30, 2017. The notes are convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date. A total of $25,000 of principal was converted into 13,157,895 shares of common stock on October 31, 2017. Currently in default. 25,000 - On October 10, 2016, the Company issued a 10% interest bearing; unsecured convertible promissory note with a face value of $300,000 (“Seventh Redwood Note”), which matures on October 10, 2017, pursuant to a Warrant Purchase Agreement by and among Redwood Management, LLC, the Company and Typenex. Pursuant to this agreement, Redwood purchased the warrants from Typenex, and Typenex provided a Satisfaction of Judgment and Release of Garnishment to release the Writ of Garnishment Typenex had placed on our transfer agent. Redwood paid installment payments to Typenex in the aggregate amount of $300,000, which were completed on, or about November 10, 2016. The principal and interest of the Seventh Redwood Note is convertible into shares of common stock at the discretion of the note holder at a price equal to the greater of (i) 60% of the lowest traded price over the 15 days prior to conversion or (ii) a fixed $0.00005 per share. The note carries liquidated damages of $1,000 per day for failure to provide certificates, and compensation for Buy-In on failure to timely deliver certificates. Principal and interest is due upon default at 50% of the lowest traded price over the previous fifteen (15) days, and an additional interest rate equal to the lesser of 2% per month (24% per annum) or the maximum rate per applicable law. This settled the dispute with Typenex. A total of $308,750, consisting of $300,000 of principal and $8,750 of interest, was converted into 135,596,882 shares of common stock on various dates between November 21, 2016 and February 24, 2017. $ - $ 275,000 On March 11, 2016, the Company received net proceeds of $90,000 in exchange for a 10% interest bearing; unsecured convertible promissory note with a face value of $105,000 (“Fifth Redwood Note”), which matures on December 11, 2016. The principal and interest is convertible into shares of common stock at the discretion of the note holder at a price equal to the greater of (i) 60% of the lowest traded price over the 15 days prior to conversion or (ii) a fixed $0.00005 per share. The note carries liquidated damages of $1,000 per day for failure to provide certificates, and compensation for Buy-In on failure to timely deliver certificates. Principal and interest is due upon default at 50% of the lowest traded price over the previous fifteen (15) days, and an additional interest rate equal to the lesser of 2% per month (24% per annum) or the maximum rate per applicable law. A total of $120,517, consisting of $105,000 of principal and $15,517 of interest, was converted into an aggregate of 47,820,025 shares of common stock at various dates between November 8, 2016 and March 13, 2017. - 27,480 Total convertible notes payable, currently in default 200,000 302,480 Less unamortized derivative discounts: 30,010 149,456 Convertible notes payable 169,990 153,024 Less: current portion 169,990 153,024 Convertible notes payable, less current portion $ - $ -
Recognized interest expense	March 31, March 31, 2018 2017 Interest on convertible notes $ 3,285 $ 2,691 Interest on related party loans 1,800 600 Derivative discounts 60,860 149,456 Total interest expense $ 64,145 $ 152,747	December 31, December 31, 2017 2016 Interest on convertible notes $ 8,531 $ 52,720 Interest on related party loans 2,010 2,400 Amortization of derivative discounts 340,961 551,149 Amortization of loan origination costs - 79,451 Amortization of beneficial conversion feature - 81,648 Amortization of OID - 36,914 Interest on judgment payable - 13,141 Total interest expense $ 351,502 $ 817,423
Debt discounts		December 31, December 31, 2017 2016 Derivative discounts $ 221,515 $ 571,183 Original issue discounts - 23,750 Loan origination costs - 57,500 Total debt discounts $ 221,515 $ 652,433

Notes Payable, Related Parties

Notes Payable, Related Parties (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Payable Related Parties Tables
Notes payable, related parties	December 31, December 31, 2017 2016 On July 6, 2015, the Company received an unsecured loan in the amount of $10,000, due on demand, bearing interest at a simple interest rate of 8%, from the Company’s CEO. $ - $ 10,000 On July 6, 2015, the Company received an unsecured loan in the amount of $10,000, due on demand, bearing interest at a simple interest rate of 8%, from the Company’s Chairman of the Board. - 10,000 On July 6, 2015, the Company received an unsecured loan in the amount of $10,000, due on demand, bearing interest at a simple interest rate of 8%, from one of the Company’s Directors. - 10,000 Total notes payable, related parties - 30,000 Less: current portion - 30,000 Notes payable, related parties, less current portion $ - $ -

Derivative Liabilities (Tables)

Derivative Liabilities (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Derivative Liabilities Tables
Summary of Changes in fair market value Derivative Liability	The following is a summary of changes in the fair market value of the derivative liability during the three months ended March 31, 2018 and the year ended December 31, 2017, respectively: Derivative Liability Total Balance, December 31, 2016 $ 221,822 Increase in derivative value due to issuances of convertible promissory notes 221,515 Increase in derivative value attributable to tainted warrants 7,103,444 Decrease in derivative value attributable to exchange of warrants (3,766,437 ) Change in fair market value of derivative liabilities due to the mark to market adjustment (1,221,021 ) Debt conversions (303,542 ) Balance, December 31, 2017 $ 2,255,781 Increase in derivative value due to issuances of convertible promissory notes 71,072 Change in fair market value of derivative liabilities due to the mark to market adjustment (700,240 ) Debt conversions (52,270 ) Balance, March 31, 2018 $ 1,574,343	Derivative Liability Total Balance, December 31, 2015 $ 150,076 Increase in derivative value due to issuances of convertible promissory notes 583,415 Change in fair market value of derivative liabilities due to the mark to market adjustment 13,816 Debt conversions (525,485 ) Balance, December 31, 2016 $ 221,822 Increase in derivative value due to issuances of convertible promissory notes 221,515 Increase in derivative value attributable to tainted warrants 7,103,444 Decrease in derivative value attributable to exchange of warrants (3,766,437 ) Change in fair market value of derivative liabilities due to the mark to market adjustment (1,221,021 ) Debt conversions (303,542 ) Balance, December 31, 2017 $ 2,255,781

Common Stock Warrants (Tables)

Common Stock Warrants (Tables)	12 Months Ended
	Dec. 31, 2017
Common Stock Warrants Tables
Summary of information Common Stock Warrants outstanding	Shares Underlying Warrants Outstanding Shares Underlying Warrants Exercisable Range of Exercise Shares Underlying Warrants Weighted Average Remaining Contractual Weighted Average Exercise Shares Underlying Warrants Weighted Average Exercise Prices Outstanding Life Price Exercisable Price $0.00001 – $1.45 64,440,000 6.01 years $ 0.1194 64,440,000 $ 0.1194
Fair value of warrant grant is estimated weighted Average Assumptions	December 31, December 31, 2017 2016 Average risk-free interest rates 1.75 % N/A Average expected life (in years) 9.22 N/A
Summary of Activity Outstanding Common stock warrants	Weighted Average Number of Exercise Shares Price Balance, December 31, 2015 53,591,455 $ 0.1463 Warrants cancelled (351,455 ) (0.18 ) Warrants expired (300,000 ) (0.96 ) Warrants exercised (22,250,000 ) (0.00001 ) Balance, December 31, 2016 30,690,000 $ 0.24407 Warrants granted 40,750,000 0.005 Warrants exercised (7,000,000 ) (0.00001 ) Balance, December 31, 2017 64,440,000 $ 0.1194 Exercisable, December 31, 2017 64,440,000 $ 0.1194

Income Taxes (Tables)

Income Taxes (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Income Taxes Tables
Deferred tax asset	The components of the Company’s deferred tax asset are as follows: March 31, December 31, 2018 2017 Deferred tax assets: Net operating loss carry forwards $ 1,725,000 $ 1,701,000 Net deferred tax assets before valuation allowance $ 1,725,000 $ 1,701,000 Less: Valuation allowance (1,725,000 ) (1,701,000 ) Net deferred tax assets $ - $ -	December 31, December 31, 2017 2016 Deferred tax assets: Net operating loss carry forwards $ 1,701,000 $ 1,516,900 Net deferred tax assets before valuation allowance $ 1,701,000 $ 1,516,900 Less: Valuation allowance (1,701,000 ) (1,516,900 ) Net deferred tax assets $ - $ -
Reconciliation between the amounts of income tax	A reconciliation between the amounts of income tax benefit determined by applying the applicable U.S. and state statutory income tax rate to pre-tax loss is as follows: March 31, December 31, 2018 2017 Federal and state statutory rate 21 % 35 % Change in valuation allowance on deferred tax assets (21) % (35) %	December 31, December 31, 2017 2016 Federal and state statutory rate 35 % 35 % Change in valuation allowance on deferred tax assets (35 )% (35 )%

Basis of Presentation and Sig31

Basis of Presentation and Significant Accounting Policies (Details) - shares	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Notes to Financial Statements
Weighted average number of common shares outstanding - basic	718,803,900	401,283,532
Plus: Potentially dilutive common shares:
Stock options and warrants	2,992,500
Weighted average number of common shares outstanding - fully diluted	721,796,400	402,283,532

Basis of Presentation and Sig32

Basis of Presentation and Significant Accounting Policies (Details 1) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Basis Of Presentation And Significant Accounting Policies Details 1
Common stock issued for services	$ 84,600	$ 70,621
Warrants issued for services, related parties	102,364	25,030
Warrants issued for services	$ 9,617	$ 14,739
Common stock issued for services on terminated offering	586,823
Total stock based compensation	$ 783,404	$ 110,390

Basis of Presentation and Sig33

Basis of Presentation and Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017	Dec. 31, 2016
State of Incorporation	Nevada
Date of Incorporation	May 10, 2010
Advertising and promotion expenses	$ 9,925	$ 67,216	$ 64,108	$ 82,246
Anti-dilutive shares	61,440,000	110,690,004
Minimum [Member]
Ownership interest			20.00%
Maximum [Member]
Ownership interest			50.00%

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	Mar. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Going Concern Details Narrative
Accumulated deficit	$ (15,762,488)	$ (16,328,812)	$ (12,565,254)
Working capital deficit	$ (1,934,048)	$ (2,616,204)

Related Party (Details Narrativ

Related Party (Details Narrative) - USD ($)	Dec. 22, 2017	Nov. 22, 2017	Oct. 19, 2016	Dec. 22, 2017	Dec. 23, 2016	Oct. 19, 2016	Jan. 29, 2016	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017	Dec. 31, 2016	Mar. 28, 2016	Feb. 10, 2016	Jul. 06, 2015
Accrued interest, related parties											$ 3,570
Equity in losses of investment in joint venture									$ (2,058)	$ (6,232)
Preferred stock, issued shares								2,000,000		2,000,000	0
Preferred stock, par value								$ 0.001		$ 0.001	$ 0.001
Common stock, issued shares								747,306,550		637,840,677	304,556,650
Common stock, par value								$ 0.00001		$ 0.00001	$ 0.00001		$ 0.00001
Exercise price				$ 0.005
Volatility rate				195.00%
Risk-free interest rate				2.01%						1.75%
Expected term				3 years 6 months						9 years 2 months 19 days	0 years
Series A Preferred Stock [Member]
Preferred stock, par value								$ 0.001		$ 0.001
Joint Venture Partner [Member]
Other receivable, related party										$ 48,778
Other receivable, Amount										44,604
Amount of original investment										2,058
Loss on other receivable										4,174
Equity in losses of investment in joint venture										(6,232)
Chief Executive Officer [Member]
Reimbursable expenses								$ 713		713	$ 306
Unsecured loan														$ 10,000
Interest rate														8.00%
Chief Executive Officer [Member] | Series A Preferred Stock [Member]
Preferred stock, issued shares							1,000,000
Preferred stock, par value							$ 0.001
Proceeds fron prefered stock							$ 1,000
Board of Directors Chairman [Member]
Amount owed								39,116		40,195	46,016
Reimbursable expenses								$ 1,075		$ 478	$ 6,167
Unsecured loan														$ 10,000
Interest rate														8.00%
Board of Directors Chairman [Member] | Series A Preferred Stock [Member]
Preferred stock, issued shares							1,000,000
Preferred stock, par value							$ 0.001
Proceeds fron prefered stock							$ 1,000
Officers and Director [Member]
Unsecured loan														$ 10,000
Interest rate														8.00%
Common Stock Issuances for Settlement of Accounts Payments [Member] | Mr. Najarian [Member]
Common stock, issued shares												600,000
Outstanding expense reimbursements												$ 13,765
Fair value of common stock												$ 9,120
Common Stock Warrants Granted [Member] | Officers and Director [Member]
Common stock, issued shares	37,250,000			37,250,000
Warrants exercisable	7 years
Fair value Black-Scholes option-pricing model	$ 102,364			$ 102,364
Fair value per share	$ 0.00275			$ 0.00275
Volatility rate	195.00%
Risk-free interest rate	2.01%
Expected term	3 years 6 months
Common Stock Warrants Granted [Member] | Officers and Director [Member] | John Pauly [Member]
Warrants granted	2,000,000			2,000,000
Exercise price	$ 0.005
Common Stock Warrants Granted [Member] | Officers and Director [Member] | Patricio Reyes [Member]
Warrants granted	4,000,000			4,000,000
Exercise price	$ 0.005
Common Stock Warrants Granted [Member] | Officers and Director [Member] | Jay Rosen [Member]
Warrants granted	1,000,000			1,000,000
Exercise price	$ 0.005
Common Stock Warrants Granted [Member] | Officers and Director [Member] | John Borza [Member]
Warrants granted	7,250,000			7,250,000
Exercise price	$ 0.005
Common Stock Warrants Granted [Member] | Officers and Director [Member] | Heidi Carl [Member]
Warrants granted	6,000,000			6,000,000
Exercise price	$ 0.005
Common Stock Warrants Granted [Member] | Officers and Director [Member] | Mitchell Felder [Member]
Warrants granted	8,500,000			8,500,000
Exercise price	$ 0.005
Common Stock Warrants Granted [Member] | Officers and Director [Member] | William Hartman [Member]
Warrants granted	8,500,000			8,500,000
Exercise price	$ 0.005
Common Stock Warrants Exercised [Member] | Chief Executive Officer [Member]
Common stock, issued shares		7,000,000	4,000,000		6,000,000	4,000,000
Common stock, par value		$ 0.00001	$ 0.00001		$ 0.00001	$ 0.00001
Proceeds from common stock		$ 70	$ 40		$ 60	$ 40
Common Stock Warrants Exercised [Member] | Board of Directors Chairman [Member]
Common stock, issued shares			4,000,000		6,000,000	4,000,000
Common stock, par value			$ 0.00001		$ 0.00001	$ 0.00001
Proceeds from common stock			$ 40		$ 60	$ 40

Patent Rights and Applications

Patent Rights and Applications (Details Narrative)	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Patents [Member]
Estimated useful life	17 years	17 years

Fair Value of Financial Instr37

Fair Value of Financial Instruments (Details) - USD ($)	Mar. 31, 2018	Dec. 31, 2017	Mar. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Assets
Cash	$ 79,221	$ 83,704	$ 209,885	$ 22,437
Liabilities
Convertible note payable, net of discounts	154,778	169,990		153,024
Notes payable, related parties
Derivative liabilities	1,574,343	2,255,781		221,822	$ 150,076
Level 1 [Member] | Fair Value, Measurements, Recurring [Member]
Assets
Cash	79,221	83,704		22,437
Total assets	79,221	83,704		22,437
Liabilities
Convertible note payable, net of discounts
Derivative liabilities
Total liabilities
Net assets and liabilities	79,221	83,704		22,437
Level 2 [Member] | Fair Value, Measurements, Recurring [Member]
Assets
Cash
Total assets
Liabilities
Convertible note payable, net of discounts	154,778	169,990		153,024
Notes payable, related parties				30,000
Derivative liabilities
Total liabilities	154,778	169,990		183,024
Net assets and liabilities	(154,778)	(169,990)		(183,024)
Level 3 [Member] | Fair Value, Measurements, Recurring [Member]
Assets
Cash
Total assets
Liabilities
Convertible note payable, net of discounts
Notes payable, related parties
Derivative liabilities	1,574,343	2,255,781		221,822
Total liabilities	1,574,343	2,255,781		221,822
Net assets and liabilities	$ (1,574,343)	$ (2,255,781)		$ (221,822)

Joint Venture (Details Narrativ

Joint Venture (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017	Dec. 31, 2016	Sep. 13, 2016
Common stock warrants			1,250,000
Strike price			$ 0.05
Capital contribution			$ 25,000
Capital description			ATS will contribute (i) technical, labor, manufacturing information and know-how required to produce the initial product, an extended duration topical pain relief patch; (ii) $5,000 worth of primary ingredients; and (iii) $5,000 worth of other materials to produce the initial prototype pain relief patches.
Equity in losses of investment in joint venture		$ (2,058)	$ (6,232)
Premier [Member]
Percentage of ownership in PBPMS					50.00%
Percentage of profit allocated from PBPMS					89.00%
ATS [Member]
Percentage of ownership in PBPMS					50.00%
Percentage of profit allocated from PBPMS					11.00%

Convertible Notes Payable (Deta

Convertible Notes Payable (Details) - USD ($)	Mar. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Total convertible note payable	$ 195,000	$ 200,000	$ 302,480
Less unamortized debt derivative discounts	40,222	30,010	149,456
Convertible note payable	154,778	169,990	153,024
Less: current portion	154,778	169,990	153,024
Convertible note payable, less current portion
On October 30 2017 Second Diamond Rock Note [Member]
Total convertible note payable	50,000	50,000
On October 30 2017 Second SEG Note [Member]
Total convertible note payable		40,000
On August 8 2017 Diamond Rock LLC[Member]
Total convertible note payable	35,000	35,000
On October 30 2017 Second RDW Note [Member]
Total convertible note payable
On August 8 2017 Special Equities Group LLC [Member]
Total convertible note payable	50,000	50,000
On August 8 2017 RDW Capital LLC [Member]
Total convertible note payable		25,000
On October 10, 2016 Unserured loan [Member]
Total convertible note payable			275,000
On March 11, 2016 Unsecured loan [Member]
Total convertible note payable			$ 27,480
On March 01 2018 First Red Diamond Note [Member]
Total convertible note payable	30,000
On March 01 2018 First SEG-RedaShex Note [Member]
Total convertible note payable	$ 30,000

Convertible Notes Payable (De40

Convertible Notes Payable (Details 1) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017	Dec. 31, 2016
Convertible Notes Payable Details 1
Interest on convertible notes	$ 3,285	$ 2,691	$ 8,531	$ 52,720
Interest on related party loans	1,800	600	2,010	2,400
Derivative discounts	60,860	149,456	340,961	551,149
Amortization of loan origination costs				79,451
Amortization of beneficial conversion feature				81,648
Amortization of OID				36,914
Interest on judgment payable				13,141
Total interest expense	$ 64,145	$ 152,747	$ 351,502	$ 817,423

Convertible Notes Payable (De41

Convertible Notes Payable (Details 2) - USD ($)	Mar. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Derivative discounts	$ 40,222	$ 30,010	$ 149,456
Interest Expense [Member]
Derivative discounts		221,515	571,183
Original issue discounts			23,750
Loan origination costs			57,500
Total debt discounts		$ 221,515	$ 652,433

Convertible Notes Payable (De42

Convertible Notes Payable (Details Narrative) - USD ($)	Mar. 01, 2018	Nov. 13, 2017	Oct. 30, 2017	Aug. 08, 2017	Jan. 03, 2017	Oct. 10, 2016	Mar. 11, 2016	Jan. 29, 2018	Oct. 31, 2017	Dec. 31, 2017	Dec. 31, 2016
Interest expense										$ 340,961	$ 749,162
Percentage of issued and outstanding shares										4.99%
November 21, 2016 and February 24, 2017 [Member] | Typenex [Member]
Converted shares						135,596,882
Converted amount						$ 300,000
Interest expense						8,750
Proceeds from convertible promissory note						$ 308,750
Series B [Member] | Common Stock [Member]
Warrant to purchase shares				10,101,011
Second RDW Note [Member]
Interest rate			8.00%
Maturity date			Jan. 31, 2018
Total amount paid			$ 50,000
Debt conversion price description			The note is convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date.
Converted shares			31,015,038
Converted amount			$ 50,000
Second SEG Note [Member]
Interest rate			8.00%
Maturity date			Jan. 31, 2018
Total amount paid			$ 10,000
Debt conversion price description			The note is convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date.
Converted shares			5,208,333					26,559,426
Converted amount								$ 40,000
Second Diamond Rock Note [Member]
Interest rate			8.00%
Maturity date			Jan. 31, 2018
Debt conversion price description			The note is convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date. Currently in default.
Converted amount			$ 50,000
RDW Capital LLC [Member]
Common stock shares purchased				10,101,011
Interest rate				8.00%
Maturity date				Nov. 30, 2017
Total amount paid				$ 25,000
Debt conversion price description				The notes are convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date.
Converted shares				13,157,895	19,230,769				13,157,895
Converted amount				$ 50,000	$ 25,000				$ 25,000
RDW Capital LLC [Member] | Series A [Member]
Warrant to purchase shares				13,333,334
RDW Capital LLC [Member] | Series B [Member]
Warrant to purchase shares				13,333,334
Special Equities Group LLC [Member]
Common stock shares purchased				10,101,011
Interest rate				8.00%
Maturity date				Nov. 30, 2017
Debt conversion price description				The notes are convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date.
Converted amount				$ 50,000
Special Equities Group LLC [Member] | Common Stock [Member]
Warrant to purchase shares				10,101,011
Special Equities Group LLC [Member] | Series A [Member]
Warrant to purchase shares				13,333,334
Special Equities Group LLC [Member] | Series B [Member]
Warrant to purchase shares				13,333,334
Diamond Rock LLC [Member]
Common stock shares purchased				10,101,011
Interest rate				8.00%
Maturity date				Nov. 30, 2017
Total amount paid				$ 15,000
Debt conversion price description				The notes are convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date.
Converted shares		7,812,500		7,812,500
Converted amount		$ 50,000		$ 50,000
Diamond Rock LLC [Member] | Common Stock [Member]
Warrant to purchase shares				10,101,011
Diamond Rock LLC [Member] | Series A [Member]
Warrant to purchase shares				13,333,334
Diamond Rock LLC [Member] | Series B [Member]
Warrant to purchase shares				13,333,334
Seventh Redwood Note [Member]
Interest rate						10.00%
Face value of unsecured convertible promissory note						$ 300,000
Maturity date						Oct. 10, 2017
Total amount paid						$ 300,000
Debt conversion price description						The principal and interest of the Seventh Redwood Note is convertible into shares of common stock at the discretion of the note holder at a price equal to the greater of (i) 60% of the lowest traded price over the 15 days prior to conversion or (ii) a fixed $0.00005 per share. The note carries liquidated damages of $1,000 per day for failure to provide certificates, and compensation for Buy-In on failure to timely deliver certificates. Principal and interest is due upon default at 50% of the lowest traded price over the previous fifteen (15) days, and an additional interest rate equal to the lesser of 2% per month (24% per annum) or the maximum rate per applicable law.
Fifth Redwood Note [Member]
Interest rate							10.00%
Face value of unsecured convertible promissory note							$ 105,000
Maturity date							Dec. 11, 2016
Debt conversion price description							The principal and interest is convertible into shares of common stock at the discretion of the note holder at a price equal to the greater of (i) 60% of the lowest traded price over the 15 days prior to conversion or (ii) a fixed $0.00005 per share. The note carries liquidated damages of $1,000 per day for failure to provide certificates, and compensation for Buy-In on failure to timely deliver certificates. Principal and interest is due upon default at 50% of the lowest traded price over the previous fifteen (15) days, and an additional interest rate equal to the lesser of 2% per month (24% per annum) or the maximum rate per applicable law.
Net proceeds							$ 90,000
Fifth Redwood Note [Member] | November 8, 2016 and December 22, 2016 [Member]
Converted shares							47,820,025
Converted amount							$ 105,000
Interest expense							15,517
Proceeds from convertible promissory note							$ 120,517
First SEG-RedaShex Note [Member]
Maturity date	May 31, 2018
Debt conversion price description	The note is convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date.
Proceeds from convertible promissory note	$ 30,000
First Red Diamond Note [Member]
Maturity date	May 31, 2018
Debt conversion price description	The note is convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date.
Proceeds from convertible promissory note	$ 30,000
Interest Expense [Member]
Total debt discounts										$ 221,515	$ 652,433

Notes Payable, Related Partie43

Notes Payable, Related Parties (Details) - USD ($)	Dec. 31, 2017	Nov. 30, 2017	Dec. 31, 2016
Total notes payable, related parties		$ 32,010	$ 30,000
Less: current portion			30,000
Notes payable, related parties, less current portion
Chief Executive Officer [Member]
Total notes payable, related parties			10,000
Board of Directors Chairman [Member]
Total notes payable, related parties			10,000
Director [Member]
Total notes payable, related parties			$ 10,000

Notes Payable, Related Partie44

Notes Payable, Related Parties (Details Narrative) - USD ($)	1 Months Ended	12 Months Ended
	Nov. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
Consisting	$ 30,000
Interest repaid	2,010
Total notes payable, related parties	$ 32,010		$ 30,000
Notes Payable, Related Parties [Member]
Interest expense		$ 2,010	$ 2,400

Derivative Liabilities (Details

Derivative Liabilities (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017	Dec. 31, 2016
Derivative Liabilities Details
Beginning Balance	$ 2,255,781	$ 221,822	$ 221,822	$ 150,076
Increase in derivative value due to issuances of convertible promissory notes	71,072		221,515	583,415
Increase in derivative value attributable to tainted warrants			7,103,444
Decrease in derivative value attributable to exchange of warrants			(3,766,437)
Change in fair market value of derivative liabilities due to the mark to market adjustment	(700,240)	$ (4,945,782)	(1,221,021)	13,816
Debt conversions	(52,270)		(303,542)	(525,485)
Ending Balance	$ 1,574,343		$ 2,255,781	$ 221,822

Derivative Liabilities (Detai46

Derivative Liabilities (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended		12 Months Ended
	Dec. 22, 2017	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017	Dec. 31, 2016
Derivative liabilities		$ 1,574,343		$ 2,255,781	$ 221,822
Change in derivative liabilities		(700,240)	$ 5,100,091	2,115,986	26,048
Change in fair market value of derivative liabilities due to the mark to market adjustment		(700,240)	(4,945,782)	(1,221,021)	13,816
Change in fair market value attributable to the warrants		(718,750)	(147,088)
Change in fair market value on convertible notes adjustment		$ 18,510	$ 7,221	4,767
Volatility	195.00%
Change in fair value in excess of convertible notes					$ 12,232
Increase in derivative value attributable to tainted warrants				7,103,444
Decrease in derivative value attributable to exchange of warrants				3,766,437
Change in fair market value in market value of the warrants				$ 1,225,788
Convertible DebentureMember | Warrant [Member]
Maturity term		2 years		2 years	2 years
Increase in trading fees (monthly)				1.00%	1.00%
Default event, Description		An event of default would occur -0-% of the time, increasing 2% per month to a maximum of 10%.		An event of default would occur -0-% of the time, increasing 2% per month to a maximum of 10%.	An event of default would occur -0-% of the time, increasing 2% per month to a maximum of 10%.
Fundamental transaction, Description		A change of control and fundamental transaction would occur initially -0-% of the time and increase monthly by -0-% to a maximum of -0-%.		A change of control and fundamental transaction would occur initially -0-% of the time and increase monthly by -0-% to a maximum of -0-%.	A change of control and fundamental transaction would occur initially -0-% of the time and increase monthly by -0-% to a maximum of -0-%.
Redeem notes, Description		The Company would redeem the notes -0-% of the time, increasing 1% per month to a maximum of 5%.		The Company would redeem the notes -0-% of the time, increasing 1% per month to a maximum of 5%.	The Company would redeem the notes -0-% of the time, increasing 1% per month to a maximum of 5%.
Exercisable target prices description		target prices of 3 to 5 times the projected reset price or higher.
Reset events description		Reset events were projected to occur by 3/31/18 and 12/31/18 – the reset provision ends 3/30/19 and the option expires 3/30/20.
Maturity description		The Holder would exercise the warrant at maturity in 2020 if the stock price was above the reset exercise price.
Convertible DebentureMember | Warrant [Member] | Minimum [Member]
Stock price		$ 0.0033		$ 0.0035	$ 0.0035
Volatility				141.00%	141.00%
Trading fees (monthly)		$ 968,718		$ 1,120,620	$ 1,120,620
Convertible DebentureMember | Warrant [Member] | Maximum [Member]
Stock price		$ 0.0063		$ 0.0081	$ 0.0081
Volatility				232.00%	232.00%
Trading fees (monthly)		$ 1,011,107		$ 1,441,388	$ 1,441,388

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative)	May 09, 2012	Dec. 22, 2017	Oct. 31, 2017USD ($)Integer	Dec. 31, 2017	Dec. 31, 2016
Agreement term		3 years 6 months		9 years 2 months 19 days	0 years
Research and Development Agreements [Member]
Contractual obligations, amount payable			$ 326,336
Contractual obligations, initial payment			$ 22,211
Contractual obligations, frequency of periodic payment			Monthly
Contractual obligations, number of installments | Integer			28
Research and Development Agreements [Member] | Minimum [Member]
Contractual obligations, periodic payments			$ 5,000
Research and Development Agreements [Member] | Maximum [Member]
Contractual obligations, periodic payments			$ 20,000
Collaborative Patent License Agreements [Member]
Sales revenue gross	10.00%
Agreement term	5 years

Changes in Stockholders_ Equi48

Changes in Stockholders’ Equity (Deficit) (Details Narrative) - USD ($)	Dec. 06, 2017	Aug. 08, 2017	Jan. 10, 2017	Dec. 13, 2016	Nov. 14, 2016	Nov. 08, 2016	Aug. 12, 2016	Apr. 11, 2016	Mar. 02, 2016	Feb. 12, 2016	Feb. 10, 2016	Dec. 22, 2017	Aug. 25, 2017	May 30, 2017	Mar. 30, 2017	Feb. 13, 2017	Dec. 23, 2016	Nov. 22, 2016	Oct. 19, 2016	Jul. 21, 2016	Apr. 19, 2016	Mar. 28, 2016	Mar. 17, 2016	Jan. 29, 2016	Dec. 26, 2017	Mar. 13, 2017	Mar. 31, 2018	Dec. 22, 2016	Dec. 31, 2017	Dec. 31, 2016
Preferred stock, par value																											$ 0.001		$ 0.001	$ 0.001
Preferred stock, authorized shares																											10,000,000		10,000,000	10,000,000
Exercise of preferred stock warrants at $0.001 per share, related parties, Amount																														$ 2,000
Interest rate												2.01%																	1.75%
Convertible note																											$ 154,778		$ 169,990	$ 153,024
Warrant exercisable term												7 years
Common stock issued on debt conversions, Amount																													423,197	737,716
Common stock issued on equity line of credit, Amount																													18,323	143,520
Exercise of warrants at $0.00001 per share, related party, Amount																													70	200
Exercise of cashless warrants at $0.00001 per share, Shares											2,248,846
Shares issued for settlement of reimbursements, related party, Amount																														$ 13,765
Shares issued for services, Shares
Shares issued for services, Amount																													84,600	$ 70,621
Shares issued for services on terminated offering, Amount																													$ 586,823
Subscriptions payable, shares																											0		63,675,678	0
Subscriptions payable, amount																													$ 273,805
Exercise of Common Stock Warrants [Member]
Exercise of cashless warrants at $0.00001 per share, Shares											2,248,846
Cashless exercise of common stock warrants exercised shares											2,250,000
Exercise of Common Stock Warrants [Member] | Board of Directors Chairman [Member]
Exercise of warrants at $0.00001 per share, related party, Shares																	6,000,000		4,000,000
Exercise of warrants at $0.00001 per share, related party, Amount																	$ 60		$ 40
Exercise of Common Stock Warrants [Member] | Chief Executive Officer [Member]
Exercise of warrants at $0.00001 per share, related party, Shares																	6,000,000	7,000,000	4,000,000
Exercise of warrants at $0.00001 per share, related party, Amount																	$ 60	$ 70	$ 40
Securities Purchase Agreement [Member]
Aggregate amount															$ 300,000
Deferred offering costs															$ 15,000
Exchange shares of common stock														30,303,033	40,000,002
Warrant exercisable term														3 years	3 years
Effective reset provision, Description															purchase price of the common stock of each tranche to the lower of (i) $0.02 or (ii) a 50% discount to the average of the three lowest closing prices in the 20 trading days prior to the reset date, which is the earlier of (i) the 7 month anniversary of the closing of each tranche of this transaction or (ii) 20 trading days after the effectiveness of each tranche.
Additional shares of common stock and warrant purchase														$ 150,000
Purchase price per share, Description														Second Closing was the lesser of (i) $0.02, subject to certain adjustments for stock splits and other similar transactions, or (ii) 50% of the closing price on the trading day immediately prior to the date of sale.
Securities Purchase Agreement [Member] | Third Closing [Member]
Trading days of common stock		15 days
Traded price of Common stock		50.00%
Interest rate		8.00%
Aggregate amount		$ 150,000
Securities Purchase Agreement [Member] | Second Closing [Member]
Trading days of common stock		15 days
Maturity date		Nov. 30, 2017
Interest rate		8.00%
Convertible note		$ 50,000
Aggregate amount		$ 150,000
Exchange shares of common stock		10,101,011
Series B Warrant [Member] | Securities Purchase Agreement [Member]
Warrant purchase														30,303,033	40,000,002
Warrant exercise price														$ 0.05	$ 0.05
Series B Warrant [Member] | First Closing [Member] | Securities Purchase Agreement [Member]
Exchange shares of common stock		13,333,334
Series A Warrants [Member] | Securities Purchase Agreement [Member]
Warrant purchase														30,303,033	40,000,002
Warrant exercise price														$ 0.03	$ 0.03
Series A Warrants [Member] | First Closing [Member] | Securities Purchase Agreement [Member]
Exchange shares of common stock		13,333,334
Redwood Fund III, Ltd One [Member]
Common stock issued for debt financing, Shares											2,400,000
Fair value of common stock											$ 38,400
Redwood Fund III, Ltd [Member]
Common stock issued for debt financing, Shares											600,000
Fair value of common stock											$ 9,600
Redwood Convertible Note [Member]
Common stock issued on debt conversions, Amount																										$ 323,197
Common stock issued on debt conversions, Shares																										142,148,242
Principal amount																										$ 302,480
Accrued Interest																										$ 20,717
Common stock issued on equity line of credit, Amount			$ 10,323	$ 25,000		$ 25,000	$ 39,520									$ 8,000		$ 25,000		$ 29,000
Common stock issued on equity line of credit, Shares			3,147,110	6,250,000		6,097,561	5,200,000									2,000,000		6,377,551		4,027,778
First JMJ Financial Note [Member]
Common stock issued on debt conversions, Shares									2,000,000														4,400,000
Principal amount									$ 13,200														$ 29,040
First JMJ Note [Member]
Common stock issued on debt conversions, Shares								2,800,000													3,159,944
Principal amount								$ 9,744													$ 10,238
Redwood Notes [Member]
Common stock issued on debt conversions, Amount																												$ 675,494
Common stock issued on debt conversions, Shares																												152,837,041
Principal amount																												$ 653,771
Accrued Interest																												$ 21,723
Diamond Rock Notes [Member]
Common stock issued on debt conversions, Shares																									57,193,766
Principal amount																									$ 100,000
Preferred Stock Issuances for Exercise of Preferred Stock Warrants, Related Parties [Member] | Board of Directors Chairman [Member]
Exercise of preferred stock warrants at $0.001 per share, related parties, Shares																								1,000,000
Exercise of preferred stock warrants at $0.001 per share, related parties, Amount																								$ 1,000
Preferred Stock Issuances for Exercise of Preferred Stock Warrants, Related Parties [Member] | Chief Executive Officer [Member]
Exercise of preferred stock warrants at $0.001 per share, related parties, Shares																								1,000,000
Exercise of preferred stock warrants at $0.001 per share, related parties, Amount																								$ 1,000
Series A Preferred Stock [Member]
Preferred stock, par value																											$ 0.001		$ 0.001
Preferred stock, authorized shares																											2,000,000		2,000,000
Series A Preferred Stock voting right																											Each share of Series A Preferred Stock is convertible, at the option of the holder thereof, at any time after the issuance of such share into one (1) fully paid and non-assessable share of Common Stock. Each outstanding share of Series A Preferred Stock is entitled to one hundred (100) votes per share on all matters to which the shareholders of the Corporation are entitled or required to vote.		100 votes per share
Series A Preferred Stock [Member] | Board of Directors Chairman [Member]
Preferred stock, par value																								$ 0.001
Series A Preferred Stock [Member] | Chief Executive Officer [Member]
Preferred stock, par value																								$ 0.001
The Special Equities Group and DiamondRock, LLC [Member]
Shares issued for services, Shares	136,470,585
Shares issued for services on terminated offering, Shares	72,794,907
Shares issued for services on terminated offering, Amount	$ 313,018
Third Party [Member] | Common Stock [Member]
Shares issued for services, Shares					2,626,867					600,000			9,000,000
Shares issued for services, Amount					$ 11,821					$ 10,800			$ 84,600
Mr. Najarian [Member]
Fair value of common stock																						$ 9,120
Shares issued for settlement of reimbursements, related party, Amount																						$ 13,765
Shares issued for settlement of reimbursements, related party, Shares																						600,000
January 17, 2018 through February 13, 2018 [Member] | The Special Equities Group and DiamondRock, LLC [Member]
Subscriptions payable, shares																													63,675,678
Subscriptions payable, amount	$ 273,805

Series A Convertible Preferre49

Series A Convertible Preferred Stock Warrants (Details Narrative ) - USD ($)	1 Months Ended
	Jan. 29, 2016	Mar. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Preferred Stock, Shares Issued		2,000,000	2,000,000	0
Preferred stock, par value		$ 0.001	$ 0.001	$ 0.001
Series A Preferred Stock [Member]
Preferred stock, par value		$ 0.001	$ 0.001
Series A Preferred Stock [Member] | Chief Executive Officer [Member]
Preferred Stock, Shares Issued	1,000,000
Preferred stock, par value	$ 0.001
Proceeds from preferred stock	$ 1,000
Series A Preferred Stock [Member] | Board of Directors Chairman [Member]
Preferred Stock, Shares Issued	1,000,000
Preferred stock, par value	$ 0.001
Proceeds from preferred stock	$ 1,000

Common Stock Warrants (Details)

Common Stock Warrants (Details) - Common Stock Warrants [Member]	12 Months Ended
	Dec. 31, 2017$ / sharesshares
Shares Underlying Warrants Outstanding | shares	64,440,000
Weighted Average Remaining Contractual Life	6 years 4 days
Weighted Average Excercise Price	$ 0.1194
Shares Underlying Warrants Exercisable | shares	64,440,000
Weighted Average Exercise Price	$ 0.1194
Minimum [Member]
Range of Exercise Prices	0.00001
Maximum [Member]
Range of Exercise Prices	$ 1.45

Common Stock Warrants (Details

Common Stock Warrants (Details 1)	1 Months Ended	12 Months Ended
	Dec. 22, 2017	Dec. 31, 2017	Dec. 31, 2016
Common Stock Warrants Details 1
Average risk-free interest rates	2.01%	1.75%
Average expected life (in years)	3 years 6 months	9 years 2 months 19 days	0 years

Common Stock Warrants (Detail52

Common Stock Warrants (Details 2) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Warrants expired weighted average exercise price	$ (0.00275)
Warrants exercisable weighted average exercise price, Ending balance		$ 0.96
Common Stock Warrants [Member]
Warrants outstanding, Beginning balance	30,690,000	53,591,455
Warrants cancelled		$ (351,455)
Warrants expired		(300,000)
Warrants granted	40,750,000
Warrants exercised	(7,000,000)	(22,250,000)
Warrant outstanding, Ending balancre	64,440,000	30,690,000
Exercisable	64,440,000
Warrants outstanding weighted average exercise price, Beginning balance	$ 0.24407	$ 0.1463
Warrants cancelled weighted average exercise price		(0.18)
Warrants expired weighted average exercise price		(0.96)
Warrants granted weighted average exercise price	0.005
Warrants exercised weighted average exercise price	(0.00001)	(0.00001)
Warrants outstanding weighted average exercise price, Ending balance	0.1194	$ 0.24407
Warrants exercisable weighted average exercise price, Ending balance	$ 0.1194

Common Stock Warrants (Detail53

Common Stock Warrants (Details Narrative) - USD ($)	Nov. 22, 2017	Oct. 19, 2016	Feb. 10, 2016	Dec. 22, 2017	Dec. 23, 2016	Oct. 19, 2016	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017	Dec. 31, 2016
Warrants to purchase common shares				37,250,000
Exercise price				$ 0.005
Warrant exercisable term				7 years
Fair value of common stock warrants				$ 102,364
Fair value per share				$ 0.00275
Volatility rate				195.00%
Risk-free interest rate				2.01%					1.75%
Expected term				3 years 6 months					9 years 2 months 19 days	0 years
Professional fee							$ 39,616	$ 41,147	$ 923,175	$ 332,650
Cancelled common shares										351,455
Cancelled common shares description										(i) $0.18, and (ii) 70% of the Market Price, which is the average of the three (3) lowest VWAPs, not less than a fixed floor of $0.0001, during the twenty (20) trading day period ending on the last complete trading day prior to the date the conversion notice is delivered, or 65% if that price is less than $0.10 per share was cancelled during the year ended December 31, 2016 pursuant to the settlement reached with Typenex.
Warrants Exercisable										300,000
Warrants exercisable price										$ 0.96
Exercise of cashless warrants at $0.00001 per share, Shares			2,248,846
Cashless exercise warrants			2,250,000
Common stock, par value			$ 0.00001				$ 0.00001		$ 0.00001	$ 0.00001
Common stock, issued shares							747,306,550		637,840,677	304,556,650
Warrants weighted average exercise price									$ 0.00275
Independent contractor One [Member]
Professional fee									$ 111,981	$ 39,769
Professional fee related to related party									$ 102,364	$ 25,030
Scientific Advisory Board [Member]
Warrants to purchase common shares				3,500,000
Exercise price				$ 0.005
Warrant exercisable term				7 years
Fair value of common stock warrants				$ 9,617
Fair value per share				$ 0.00275
Volatility rate				195.00%
Risk-free interest rate				2.01%
Expected term				3 years 6 months
Mitchell Felder [Member]
Warrants to purchase common shares				8,500,000
William Hartman [Member]
Warrants to purchase common shares				8,500,000
Heidi Carl [Member]
Warrants to purchase common shares				6,000,000
John Borza [Member]
Warrants to purchase common shares				7,250,000
Jay Rosen [Member]
Warrants to purchase common shares				1,000,000
Patricio Reyes [Member]
Warrants to purchase common shares				4,000,000
John Pauly [Member]
Warrants to purchase common shares				2,000,000
Common Stock Warrants Exercised [Member] | Board of Directors Chairman [Member]
Common stock, par value		$ 0.00001			$ 0.00001	$ 0.00001
Common stock, issued shares		4,000,000			6,000,000	4,000,000
Proceeds from common stock		$ 40			$ 60	$ 40
Common Stock Warrants Exercised [Member] | Chief Executive Officer [Member]
Common stock, par value	$ 0.00001	$ 0.00001			$ 0.00001	$ 0.00001
Common stock, issued shares	7,000,000	4,000,000			6,000,000	4,000,000
Proceeds from common stock	$ 70	$ 40			$ 60	$ 40

Income Taxes (Details)

Income Taxes (Details) - USD ($)	Mar. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Deferred tax assets:
Net operating loss carry forwards	$ 1,725,000	$ 1,701,000	$ 1,516,900
Net deferred tax assets before valuation allowance	1,725,000	1,701,000	1,516,900
Less: Valuation allowance	(1,725,000)	(1,701,000)	(1,516,900)
Net deferred tax assets

Income Taxes (Details 1)

Income Taxes (Details 1)	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Taxes Details 1
Federal and state statutory rate	21.00%	35.00%	35.00%
Change in valuation allowance on deferred tax assets	(21.00%)	(35.00%)	(35.00%)

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Taxes Details Narrative
Federal net operating losses	$ (4,930,000)	$ (4,860,000)	$ 4,334,000
Federal net operating losses expire	2,031	2,031

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Jan. 03, 2018	Jan. 10, 2017	Dec. 13, 2016	Nov. 08, 2016	Aug. 12, 2016	Apr. 24, 2018	Mar. 01, 2018	Jan. 29, 2018	Feb. 13, 2017	Nov. 22, 2016	Jul. 21, 2016	Dec. 31, 2017	Dec. 31, 2016	Mar. 31, 2018	Dec. 06, 2017
Common stock issued on equity line of credit, Amount												$ 18,323	$ 143,520
Subscriptions payable, shares												63,675,678	0	0
Subscriptions payable, amount												$ 273,805
Redwood Convertible Note [Member]
Common stock issued on equity line of credit, Amount		$ 10,323	$ 25,000	$ 25,000	$ 39,520				$ 8,000	$ 25,000	$ 29,000
Common stock issued on equity line of credit, Shares		3,147,110	6,250,000	6,097,561	5,200,000				2,000,000	6,377,551	4,027,778
The Special Equities Group and DiamondRock, LLC [Member] | January 17, 2018 through February 13, 2018 [Member]
Subscriptions payable, shares												63,675,678
Subscriptions payable, amount															$ 273,805
Subsequent Event [Member] | Redwood Convertible Note [Member]
Common stock issued on equity line of credit, Amount		$ 10,323
Common stock issued on equity line of credit, Shares		3,147,110
Subsequent Event [Member] | Second SEG Note [Member]
Debt conversion converted instrument, shares issued								26,559,426
Debt conversion converted amount								$ 40,000
Subsequent Event [Member] | First RDW Note [Member]
Debt conversion converted instrument, shares issued	19,230,769
Debt conversion converted amount	$ 25,000
Subsequent Event [Member] | Two investors [Member]
Proceeds from sale of convertible notes							$ 60,000
Subsequent Event [Member] | Two investors [Member] | Securities Purchase Agreement [Member]
Proceeds from sale of convertible notes						$ 60,000
Interest rate						8.00%
Maturity date						May 31, 2018
Debt conversion price description						The notes are convertible at 50% of the lowest traded price of the Common Stock in the fifteen (15) Trading Days prior to the Conversion Date.
Subsequent Event [Member] | Investors [Member]
Sale of addtional convertible notes in future							240,000
Subsequent Event [Member] | Investors [Member] | Securities Purchase Agreement [Member]
Proceeds from sale of convertible notes							$ 60,000
Sale of addtional convertible notes, description							The investors will buy additional convertible notes for an aggregate of $60,000 within five trading days of our filing a registration statement to cover the investors’ shares of common stock issuable upon conversion of the convertible notes. Within five trading days of the registration statement being declared effective, the investors will buy additional convertible notes for an aggregate of $180,000.
Subsequent Event [Member] | The Special Equities Group and DiamondRock, LLC [Member] | January 17, 2018 through February 13, 2018 [Member]
Subscriptions payable, shares												63,675,678
Subscriptions payable, amount												$ 273,805